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 Leucine-rich repeats (LRR) are protein-protein interaction domains of 20-29 
amino acid residues in length, found in proteins with diverse structure and functions. 
An emerging group of surface proteins with an ectodomain containing LRR repeats 
and motifs were found to be interestingly and specifically enriched in the central 
nervous system (CNS). AMIGO (Amphoterin-induced gene and ORF) is a type one 
transmembrane protein with an ectodomain containing six LRRs, followed by a 
single immunoglobulin (Ig)-like domain located adjacent to the transmembrane 
domain. AMIGO has two paralogues, named AMIGO-2/Alivin and AMIGO-3. 
Immunoblot, immunohitochemical and immunofluorescence analysis with antibodies 
raised against the short cytoplasmic region of AMIGO showed that AMIGO protein 
levels are developmentally regulated and is present in multiple cell types in the brain. 
Primarily enriched in multiple neuronal subtypes, distinct staining signals could also 
be found in astrocytes and oligodendrocytes (both in tissue sections and in culture). 
Neuronal AMIGO is targeted to both axons and dendrites. The subdomains of 
AMIGO’s ectodomain, however influences its polarized targeting in primary cortical 
neurons. Exogenously expressed full length (AMIGO-FL) and Ig domain-deleted 
AMIGO (AMIGO-LRR) localize to preferably to dendrites, while a LRR-deleted 
(AMIGO-Ig) mutant is preferentially targeted to axons. When expressed in Neuro2A 
neuroblastoma cells, cell surface expression of AMIGO-Ig is immediately prominent. 
Both AMIGO-FL and AMIGO-LRR however assume a more intracellular 
 IX
morphology. Silencing of AMIGO expression for appeared to retard dendritic growth 
of primary cortical neurons.  
 The Nogo-66 receptor 2 (NgR2) is a LRR containing, glycosylphosphatidyl 
inositol (GPI)-anchored surface protein which is a paralogue of the better known and 
studied Nogo-66 receptor (NgR1), which is the receptor of myelin-associated axonal 
growth inhibitor in adult CNS myelin. NgR1 is known to function through its 
association with LINGO-1, which like AMIGO, has multiple LRR repeats and a 
single Ig-like domain. Co-immunoprecipitation (Co-IP) experiments suggest that 
NgR2 also interacts with LINGO-1 as well as p75NTR, another known NgR1 
co-receptor. After induction of neurite growth with retinoic acid, neurite extension 
and cell adhesion of Neuro2A cells co-expressing both NgR2 and LINGO-1 grown 
on MAG-Fc coated coverslips were greatly impaired. However, co-expression of 
NgR2 and a dominant-negative form of LINGO-1 have no such neurite growth 
inhibitory effect. Our results showed that NgR2 could transducer a neurite growth 
inhibitory signal by engaging LINGO-1. 
 Collectively, work reported in this thesis sheds new light on two 
brain-enriched LRR domains containing proteins that have, generally, opposite 
effects on neurite growth. Studies along these lines would be expected to provide 
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The mammalian brain is the most sophisticated organ ever to evolve within the 
animal kingdom. In the brain, specialized cell types performs multiple specialized 
functions that together support the brain’s role as a command center for the organism’s 
sensory, motor and cognitive operations. There are several families of genes whose 
products are specifically enriched in the brain. Even amongst ubiquitously expressed 
genes, there may exist brain-specific spliced isoforms, or paralogues. These brain-
enriched gene products undoubtedly have specific functions that collectively contribute 
to the unique physiology of brain tissues. This thesis describes studies on two leucine-
rich repeat (LRR) containing proteins that are brain-enriched, namely the Nogo-66 
receptor isoform 2 (NgR2) and the Amphoterin-induced gene and ORF (AMIGO). 
 
1.1 LRR domain containing proteins 
Leucine-rich repeats (LRR) are solenoid-type motifs present in a number of 
proteins with diverse functions and cellular locations (Kobe and Deisenhofer, 1994; 
Buchanan and Gay 1996; Kajava, 1998; Kobe and Kajava, 2001). The LRRs are 
generally 20-29 amino acids in length, and contain a conserved sequence of 
LxxLxLxxN/CxL (where x can be any amino acid and L could also be replaced by V, I 
or F) (Kobe and Kajava, 2001). Structurally, each LRR consists of a β-strand and an α-
helix connected by loops, and the LRR repeats are generally arranged in a curved, 
horseshoe-shaped structure parallel to a common axis. The LRR repeats appear to be a 
structural framework to support protein-protein interactions. LRR motifs are found in a 
large number of proteins, and these could be divided into seven subfamilies based on 
Chapter1                                                                                                         Introduction 
 3
the consensus sequences of the repeats, its species origin and the cellular localization 
(Kobe and Kajava, 2001).  
One subclass of LRR proteins has 23-27 amino acids in each LRR repeat, and is 
expressed extracellularly in animals and fungi (Kobe and Kajava, 2001). Many recently 
identified LRR proteins belong to this subclass (Fig 1-1). Some LRR domain 
containing, plasma membrane localized proteins have a more exclusive brain-enriched 
expression than others, implying specific functions in the central nervous system 
(CNS). These LRR proteins perform diverse roles in the developing and adult brain, 
function in promoting as well as inhibiting neuronal growth. 
An example of LRR-containing neuronal growth inhibitors are the neuronal cell 
surface Nogo-66 receptor (NgR1) (Fournier et al., 2001) and one of its cognate ligand, 
the oligodendrocyte myelin glycoprotein (OMgp) (Vourc'h and Andres, 2004). These 
form an inhibitory axis of signaling that underlies inhibition of axonal growth 
regeneration after CNS injury (Filbin, 2003). NgR1 is a member of a family of 
homologous glycosylphosphatidyl inositol (GPI)-anchored, LRR-containing proteins 
with very similar domain structures (Lauren et al., 2003; Pignot et al., 2003; Barton et 
al., 2003), while OMgp is another LRR-containing GPI-anchored protein. The other 
known NgR1 ligands are Nogo-66 and the myelin-associated glycoprotein (MAG) 
(Filbin, 2003). The OMgp/Nogo/MAG-NgR1 axis represents one major signaling 
pathway whereby the myelin-rich adult CNS environment inhibits regeneration of 
injured CNS neurons (Filbin, 2003; McGee and Strittmatter, 2003; Hunt et al., 2002). 
Contrasting to the neuronal growth inhibition by NgR1, members of the Trk 
receptors are LRR domain-containing receptor tyrosine kinases that transmit survival 
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and growth signals of the neurotrophin family of ligands in most neurons (Teng and 
Hempstead, 2004). The LRR-containing secreted protein Slit (Wong K et al., 2002; 
Howitt et al., 2004), functioning through the roundabout (Robo) membrane receptors, is 
a well-known axonal guidance molecule that functions in modulating axonal branching 
and cell migration (Piper and Little, 2003). Recently, a family of six structurally related 
mice LRR-containing, transmembrane proteins have been described. These proteins 
also have homology to Trk in their intracellular domain, and are fittingly named Slitrks 
(Aruga and Mikoshiba, 2003). The Slitrks are enriched in different parts of the brain 
and appear to have contrasting roles in modulating neurite outgrowth (Aruga and 
Mikoshiba, 2003). 
We have noted a distinct class of CNS-enriched, type 1 membrane proteins with 
leucine-rich repeats and a domain usually associated with cell adhesion molecule (Chen 
et al., 2006a) (Fig 1-2). These include the AMIGO (Alivin) family, the LRR and Ig 
domain-containing, Nogo receptor interacting protein (LINGO) family, ligand for netrin 
G1 (NGL-1), the neuronal leucine-rich repeat (NLRR) proteins and photoreceptor-
associated LRR protein superfamily PAL. All these have a number of LRR repeats 
flanked by a leucine-rich repeat (LRR)-type N-terminal domain (LRRNT) and a 
leucine-rich repeat (LRR)-type C-terminal domain (LRRCT). Furthermore, all these 
harbor a single C2-type immunoglobulin (Ig)-like domain. The NLRRs and PAL have, 
in addition, a fibronectin type III (FN-III)-like repeat. Another related family, the 
fibronectin-like domain and leucine-rich repeat containing transmembrane proteins 
(FLRTs), has a FN-III repeat but no Ig-like domains (Fig 1-2). 
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Many of these newly identified LRR proteins have not yet been extensively 
characterized. However, the structural similarity tells us that they may have important 
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Figure 1-1 Nearest neighbour dendrogram (generated by the MegAlign program 
of DNASTAR) of the CNS-enriched LRR domain-containing proteins 
Type 1 transmembrane LRR and Ig-like domain and/or FN-III domain containing proteins 
together with a number other brain-enriched LRR-containing proteins (such as OMgp, the 
Nogo-66 receptor paralogues NgR1, NgR2 and NgR3 and Slit) are shown here. Those proteins 
not described in the text include nyctalopin (a gene mutated in congenital stationary night 
blindness) (Zeitz et al., 2003) and suprachiasmatic nucleus circadian oscillatory protein (SCOP, 
a brain-enriched protein which interacts with K-Ras (Shimizu et al., 2003). Opticin is a small 
LRR proteoglycan expressed exclusively in the eye (Reardon et al., 2000), while synleurin is a 
ubiquitously expressed LRR-containing transmembrane protein which when ectopically 
expressed in cells intensifies their response to cytokines (Wang et al., 2003). LRRC4 (or 
NAG14) and LRRC4B (or HSM802162) are paralogues of NGL-1. Interestingly, LRRC4 has 
been shown to be exclusively expressed in the brain, is downregulated in brain tumor tissues 
and may have a role in suppression of CNS tumors (Zhang et al., 2005). Ribonuclease inhibitor 
(RI) contains the prototypic LRR domain and is included for comparison. In the databases, one 
encounters various nomenclatures and annotations that may point to the same gene. We adopt 
the most commonly use nomenclature in the primary literature. Note, however, that according to 
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the nomenclature of the Mouse Genome Infomatics (MGI), NLRR1–NLRR3 corresponded to 
the genes officially annotated as LRRN1–LRRN3. LRRN4 (not shown) is similar in sequence 
with leucine-rich (LR) repeats and calponin homology (CH) domain containing 4 (LRCH4). 
LRRN5 is GAC-1 as mentioned in the text. LRRN6A is LINGO-1, LRRN6B is LINGO-3, and 
LRRN6C is LINGO-2 while LRRN6D is LINGO-4. A human NLRR-5 clone reported in 
Hamano et al. (2004) is actually LINGO-2. This figure is adapted from candidate’s own review 
article- Chen, Y., Aulia, S., Li, L. and Tang, B.L. (2006a) AMIGO and friends: An emerging family of 
brain-enriched, neuronal growth modulating, type I transmembrane proteins with leucine-rich repeats 





































Figure 1-2 Schematic diagram showing the domain organization of representatives 
of the group of LRR-containing proteins with cell-adhesion molecule-like domains.   
NGL-1 with a potential intracellular PDZ binding motif (ETQI), functioning together with 
netrin G1, is important for the growth of thalamocortical neurons (Lin et al., 2003). Leucine-
rich repeats and immunoglobulin-like domains 1 (LRIG-1) and its likely Drosophila homologue 
Kekkon (Musacchio and Perrimon, 1996) bind to the epidermal growth factor (EGF) receptor 
and inhibits its signaling (Gur et al., 2004; Laederich et al., 2004). The FLRTs have a conserved 
tyrosine kinase phosphorylation site at their cytoplasmic domain which could be a potential 
substrate for FGFR. FLRT-3 regulate neurite outgrowth of sensory neurons of the peripheral 
nervous system (Robinson et al., 2004) and is upregulated during peripheral nerve injury (but 
not in CNS nerve injury). NLRR proteins are largely, but not exclusively brain-enriched 
(Taguchi et al., 1996). NLRR-1 and NLRR-3 have a conserved endocytosis motif at the 
cytoplasmic tail that is not present in NLRR-2. The latter has instead a putative WW domain, a 
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protein interaction motif binding to polypeptide stretches that are proline-rich (Ilsley et al., 
2002). PAL is a retina specific protein appeared to be correlated with the development of the 
photoreceptor outer segments. The protein is distributed diffusely on the disk membrane in the 
lamellar regions (Gomi et al., 2000). Not much is known yet about the actual physiological 
function of PAL although it is likely an adhesion molecule functioning specifically in retinal 
morphogenesis. AMIGO and LINGO family will be discussed in section 1.2 and section 1.3.6. 
This figure is adapted from candidate’s own review article-Chen, Y., Aulia, S., Li, L. and Tang, B.L. 
(2006a) AMIGO and friends: An emerging family of brain-enriched, neuronal growth modulating, type I 
transmembrane proteins with leucine-rich repeats (LRR) and cell adhesion molecule motifs. Brain 




1.2 Amphoterin-induced gene and ORF (AMIGO) 
Amphoterin-induced gene and ORF (AMIGO) is a brain-enriched type I 
transmembrane protein. This 493 amino-acid polypeptide has six extracellular leucine-
rich repeats (LRR) domain flanked by LRRNT and LRRCT, a single immunoglobulin-
like (Ig) domain, one transmembrane domain and a cytoplasmic tail (Fig 1-2). It was 
first identified by ordered differential display (ODD; Matz et al, 1997) as a gene whose 
transcript was upregulated when hippocampal neurons were grown on amphoterin-
coated surfaces (Kuja-Panula et al., 2003).  The amino acid sequence is highly 
conserved amongst mammals. The rat and mouse AMIGO share 95% identity and the 
murine sequence are around 89% identical to the human AMIGO. The entire 
transmembrane domain and the cytoplasmic tail are 100% identical between the murine 
and human AMIGOs (Kuja-Panula et al., 2003). AMIGO appears to be a member of a 
family of three paralogues with similar domain structures. Similarity at the amino acid 
level between AMIGO to AMIGO-2 and AMIGO-3 is around 50%. The most 
conserved regions between the three proteins are the LRR domain, the transmembrane 
region, and some parts of the intracellular domain. AMIGO is almost exclusively 
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expressed in CNS. The other family members AMIGO-2 and -3 are more widely 
distributed but are also brain-enriched. Members of AMIGO family exhibit both 
homophilic and heterophilic binding ability to each other, suggesting their functions in 
cell adhesion in CNS and facilitating neuronal growth.  
The non-brain enriched AMIGO-2 has been independently identified as Alivin-1 
(Ali1) by a different group of researchers using differential display screening for genes 
involved in depolarization and NMDA-dependent survival of cerebellar granule neurons 
(CGN) (Ono et al., 2003). The authors named the gene alivin-1 (ali1), after “alive” and 
“activity dependent leucine-rich repeat and Ig superfamily survival related protein, and 
noted the existence of its homologues alivin-2 and alivin-3 in the database. Alivin-
1/AMIGO-2 promotes depolarization-dependent survival of cerebellar granule neurons, 
perhaps also hippocampal neurons and the granule cells of the dentate gyrus where it is 
expressed. Expression of alivin-1 transcripts in cultured cerebellar granule neurons 
(CGN) is neuronal activity-dependent, and is modulated by KCl and/or NMDA 
concentrations in the culture medium. Alivin-1/AMIGO-2 expression is tightly 
correlated by depolarization-dependent survival and inhibited when their spontaneous 
electrical activity was blocked by the Na+ channel toxin tetrodotoxin. Interestingly 
Alivin-1/AMIGO-2 is subcellularly localized mainly in nuclear fraction and plasma 
membrane enriched fraction in rat brain.  
AMIGO-2/Alivin-1 was also identified by another group in a different context. 
And was named gene differentially expressed in human gastric adenocarcinomas 
(DEGA). DEGA/AMIGO-2 is expressed in approximately 45% of tumor versus normal 
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tissue from gastric cancer patients (Rabenau et al., 2004) which implies that it has an 
anti-apoptotic or survival promoting role in epithelial cells. 
 
1.3 The Nogo-66 receptor family and Nogo receptor homologue 2 
(NgR2) 
1.3.1 Inhibition of axonal regeneration and glia scar formation in CNS 
injury 
It is well established that adult mammalian peripheral nervous system (PNS) can 
regenerate successfully after injury. But regeneration is dismally poor in the central 
nervous system (CNS) (Schwab and Bartholdi, 1996). Recent studies have revealed 
several molecular pathways that affect the structural plasticity, including both short-
range remodeling and long distance axon regeneration (Yiu and He, 2006). A major 
reason why CNS neurons do not regenerate lies in the non-permissive environment for 
neuritogenesis in the adult CNS. The inhibition of axonal regeneration occurs by the 
interaction of inhibitory ligands expressed by oligodendrocytes in the myelin structure 
and the responsive receptors expressed on neurons. Increasing evidence shows that 
some repulsive cues in axonal pathfinding during development might restrict also axon 
regeneration in adulthood. A class of molecules, collectively known as myelin-
associated inhibitors (MAI) expressed by oligodendrocytes are exposed during the early 
phase of injury, and their downstream signaling induces neuronal growth cone collapse. 
A number of glial scar and myelin-associated inhibitors of neuronal regeneration have 
now been identified. These include chondroitin sulfate proteoglycans (CSPGs), myelin-
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associated glycoprotein (MAG), oligodendrocyte myelin glycoprotein (OMgp), 
tenascin, and Nogo (Asher et al, 2001; Fournier and Strittmatter; 2001, Sandvig et al., 
2004; Yiu and He, 2006). In addition, reactive astrocytes and inflammatory cells form a 
glial scar over time at the lesion site that might acts as an additional barrier to axonal 
regeneration. 
 
1.3.2 Overview of Nogo-66 receptor mechanism for myelin inhibition 
Nogo-66 receptor (NgR1) and its homologues are GPI-linked proteins expressed 
by many types of neurons. NgR1 was firstly identified by its binding affinity to Nogo’s 
extracellular domain, termed Nogo-66 (Fournier et al., 2001) (see Fig 1-3). The 
interaction of between NgR1 and Nogo-66 induces growth cone collapse of certain but 
not all types of neurons. Further work showed that myelin-associated glycoprotein 
(MAG) and Oligodendrocyte Myelin glycoprotein (OMgp) are also ligands for NgR1 
(Liu et al., 2002;Domeniconi et al., 2002; Wang et al., 2002a). As a GPI-linked protein 
which lacks an intracellular domain, NgR1 could signal only with other transmembrane 
proteins acting as co-receptors. Two members of the tumor necrosis factor receptor 
(TNFR) family, namely the p75 neurotrophin receptor (p75NTR) (Wang et al., 2002b; 
Wong ET et al., 2002) and TROY /TAJ (Shao et al., 2005; Park et al., 2005), as well as 
a novel LRR containing protein LINGO-1 (Mi et al., 2004), were all found to interact 
with NgR1 and act as its co-receptors.  
The signaling processes of NgR1-mediated neurite growth inhibition and growth 
cone collapse are gradually being understood (Yiu and He, 2006). An MAI ligand likely 
engages NgR1 together with its co-receptors. This initiates a cascade of signaling events 
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that result in the activation of RhoA and its downstream effectors which in turn 
modulate actin dynamics. Interestingly, suppressing the kinase function of the 
epidermal growth factor receptor (EGFR) blocks the activities of MAI in inhibiting 
neurite outgrowth. The inhibitors trigger the phosphorylation of EGFR in a calcium-
dependent manner which might also activate protein kinase C (PKC) (Koprivica et al., 
2005). This Protein kinase C is activated and induces the cleavage of p75NTR by α- and 
γ- secretases. The intracellular domain of p75NTR acting as a displacement factor that 
releases Rho from Rho-guanine dissociation inhibitor (Domeniconi et al., 2005). Thus, 
the small GTPase RhoA is directly activated. The activation of downstream kinases 
such as RhoA associated kinase (ROCK) further signals through LIM kinase and 
Slingshot (SSH) phosphatase, which regulate the actin depolymerization factor cofilin 
and cause growth cone collapse (Hsieh et al., 2006).  
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Figure 1-3 The axon regeneration inhibition pathway through NgR1/NgR2 
complex.  
Nogo-A, MAG, OMgp were NgR1 ligands expressed by oligodendrocytes. The NgRs are GPI-
linked proteins and the signal transduction is through its co-receptor LINGO-1 and 
p75NTR/TROY. GPI-linker anchors NgRs in the lipid raft where Rho family proteins are 
enriched. The downstream activation of RhoA GTPases in turn regulates the organization of the 
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actin cytoskeleton and microtubules, therefore induces growth cone collapse or repulsion and 
inhibits axonal growth. Figure adapted from candidate’s own review article-Chen, Y., Aulia, S. and 
Tang, B.L. (2006b) Myelin-associated glycoprotein-mediated signaling in central nervous system 
pathophysiology. Mol. Neurobiol. 34:81-91.  
 
 
1.3.3 Nogo-66 receptor and family members 
NgR1 is a 473 amino-acid long protein containing an N-terminal signal 
sequence, a leucine-rich repeat (LRR)-type N-terminal domain (LRRNT) with 8 LRR 
domains, a cysteine-rich LRR-type C-terminal flanking domain (LRRCT), a unique C-
terminal region, and a glycosylphosphatidyl inositol (GPI) anchorage site (Fig 1-4) 
(Fournier et al., 2002a). Three groups have identified two NgR1 homologues 
independently. These were named NgR2 and NgR3 (Barton, et al., 2003) or NgRH1, 
NgRH2 (Pignot et al., 2003) or NgRL3 and NgRL2 (Lauren et al., 2003). The 
nomenclature of NgR1, NgR2 and NgR3 shall be followed in the thesis. NgR1 
homologues NgR2 and NgR3 are 420 amino acids and 445 amino acids in length, 
respectively. Both are shorter than NgR1 in the C-terminal unique region (Fig 1-4). The 
amino acid identity among NgR1, NgR2 and NgR3 is about 44% to 58%, whereas this 
identity between the NgRs and other proteins of the LRR superfamily is about 30% 
(Lauren et al., 2003). All NgRs are highly conserved between human and mouse, 
showing 87% or more identity in amino acid sequence (Lauren et al., 2003). The LRR 
domain of NgR1 adapts a banana shape with elongation and curvature arising from the 
LRRNT and LRRCT domains (Barton et al., 2003, see Fig 1-4 C).  
Chapter1                                                                                                         Introduction 
 15
 
Figure 1-4 Multiple sequence alignment (ClustalW) and schematic structural 
illustration of of human NgR1, NgR2 and NgR3. 
A: The sequence alignment (ClustalW) of human NgR1 NgR2 and NgR3. Signal sequences 
(underlined),  LRRNT, LRR 1-8, LRRCT and  the hydrophobic tail/GPI signal sequences at the 
C-terminal (bold) are indicated in the diagram. B: Comparison schematic diagram showing the 
domain organization of NgR1, NgR2 and NgR3. Yellow box: signal peptide, Green box: 
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LRRNT and LRRCT, blue box: LRR repeats, stalk: C-terminal unique domain, waved line: GPI 
linker. C: The banana shaped 3D structure of NgR1 LRR domain shown with α-helices and β-
sheets for each LRR repeats (picture from NCBI PDB: 1P8T presented using the program 
Cn3D4.1) 
 
Like NgR1, both NgR2 and NgR3 are enriched and almost exclusively 
expressed in the brain. NgR2 expression was also detectable in liver (Pignot et al., 
2003). All these genes are either not detected or found at low levels in other peripheral 
tissues, such as skeletal muscle, spleen, kidney, lung and placenta.  
NgR2 has been shown to be a functional receptor for MAG (see section 1.3.4 
below) in a sialic acid-dependent manner by another group of researchers (Venkatesh et 
al., 2005). MAG-Fc (MAG ectodomain fused to human Ig constant domain Fc), but not 
other NgR1 ligands (Nogo-66 or OMgp) binds to NgR2 expressing cells.  In affinity 
Co-precipitation studies, MAG-Fc pulled down both NgR1 and NgR2 in a reciprocal 
manner. The binding of MAG to NgR2 infected dorsal root ganglion (DRG) neurons 
occur in a sialic acid-dependent, Vibrio cholerae neuraminidase (VCN) sensitive 
manner.  Furthermore, MAG inhibited the neurite growth of the NgR2 infected CGN 
neurons. These results showed that NgR2 is a functional receptor for MAG in neurite 
growth inhibition. Domain dissection analysis revealed that both LRR domains and the 
C-terminal unique domain are necessary for high affinity MAG binding. It is yet 
unclear, however, if NgR2 also engages the co-receptors, p75NTR and/or LINGO-1 in its 
action. This is one of the points examined in the thesis (see section 4.3). 
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1.3.4 The myelin-associated inhibitor (MAI) Ligands: MAG, Nogo and 
OMgp 
Three myelin-associated inhibitors (MAI) are known ligands of NgR1. These 
include Nogo-66 (Fournier, et al., 2001), which is the 66 amino-acid loop between two 
tentative transmembrane domains of Nogo (GrandPre et al., 2000), myelin-associated 
glycoprotein (MAG) (Liu, et al., 2002; Domeniconi et al., 2002; Filbin, 2003) and 
Oligodendrocyte-myelin glycoprotein (OMgp), another ligand of NgR1 (Wang et al., 
2002a), is also a LRR containing protein. 
Myelin-associated glycoprotein (MAG) is a member of the sialic acid-dependent 
immunoglobulin-like lectins (siglec) family (Crocker 2002; Vyas and Schnaar, 2001). 
Designated siglec-4a, many, but not all, of MAG’s interaction with neurons occurs in a 
sialic acid-dependent manner (DeBellard et al., 1996). It is a transmembrane protein 
that exists in two alternatively spliced isoforms: small (S) (582 residues) and large (L) 
(626 residues) MAG. Both forms differ only in the cytoplasmic C-terminus, but have 
the same N-terminal extracellular domain which contains 4 immunoglobulin-like C2 
type domains and contains 1 immunoglobulin-like V-type domain (Fig 1-3). 
Nogo is one of the most potent myelin-derived inhibitor in the adult CNS 
(Fournier, et al., 2001). Its inhibitory activity was first described about 20 years ago 
(Caroni and Schwab, 1988).  Three major splice isoforms, Nogo-A, Nogo-B and Nogo-
C were derived from a single gene. Nogo is a member of the reticulon family (Chen et 
al., 2000; GrandPre et al., 2000), a group of endoplasmic reticulum associated protein 
whose functions are unclear. All three isoforms of Nogo share the same C-terminus 
region. The topology of Nogo-A has remained controversial but the 66 amino-acid loop 
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(Nogo-66) between the two transmembrane domains likely projects extracellularly 
(GrandPre et al., 2000; Hu et al., 2005). Both the acidic amino terminus of Nogo-A 
(Amino-Nogo) and the extracellular Nogo-66 exhibits the ability to inhibit axon 
regeneration (Fournier et al., 2001) 
OMgp is an oligodendroglia protein first identified by Mikol and Stefansson 
(1988). It is highly expressed by mature oligodendrocytes positive for myelin basic 
protein (MBP) and found to be an inhibitor of neurite outgrowth (Habib et al., 1998; 
Kottis, 2002). Like NgR1, OMgp is a GPI-linked protein containing 8 LRR domains 
(Mikol et al., 1990a, b; Vourc’h and Andres, 2004). The LRR domain of OMgp was 
found to be sufficient to confer strong binding to NgR1-expressing cells (Wang et al., 
2002a). In addition, its C-terminal domain with serine-threonine repeats was also able to 
bind weakly to NgR1-expressing cells (Wang et al., 2002a). These domains could act 
independently through NgR1 to induce growth cone collapse and inhibit neurite 
outgrowth. OMgp is predominantly localized on the surfaces of oligodendrocytes and 
axon-adjacent myelin layers suggesting that OMgp is a physiological ligand of NgR1 
(Wang et al., 2002a). In vitro study shows removal of NgR1 by cleaving its GPI 
membrane anchor results in loss of the growth-inhibitory action of all three proteins 
(Fournier et al., 2002b). 
 
1.3.5 The coreceptors of NgR1: p75NTR and TROY/TAJ 
As GPI-anchored proteins such as NgR1 lack the transmembrane and 
intracellular part, they must engage co-receptors in order to facilitate the signal 
transduction through the plasma membrane. Earlier study suggested that the p75 
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neurotrophin receptor (p75NTR) interact with MAG indirectly, and p75NTR is required in 
MAG induced neurite outgrowth inhibition (Yamashita et al, 2002). Co-
Immunoprecipitation (Co-IP) studies show that p75NTR and NgR1 interact directly. The 
blocking of the p75NTR –NgR1 interaction reduces the known NgR1 ligands’ inhibitory 
activity in rat primary neurons (Wong ST et al., 2002; Wang et al., 2002b).  p75NTR is 
thus a functional NgR1 co-receptor. 
p75NTR is a transmembrane protein of the Tumor Necrosis Factor (TNF) receptor 
family. It is a rather promiscuous receptor and is firstly known to bind weakly to growth 
factors of the neurotrophin family. p75NTR is highly expressed in developing nervous 
system. However, its expression level is decreased in adulthood and is only present in a 
small subpopulation of mature neurons (Roux and Barker, 2002, Chao 2003). Other 
than p75NTR, two groups identified another TNF receptor TROY/TAJ (Park et al., 2005; 
Shao et al., 2005), which is a more likely physiological partner of NgR1 in 2005. 
TROY, also named as TAJ/TNFRSF19, is an orphan receptor of the TNF receptor 
family which closely resembles p75NTR (Eby et al., 2000; Kojima et al., 2000). 
TROY/TAJ is more widely expressed and abundant in adult brain (Shao et al., 2005) 
and therefore more likely to interact with NgR1 and mediate the inhibitory effects its 
ligands. 
 
1.3.6 The NgR1 coreceptor LINGO-1 and its functions 
In non-neuronal cells such as the COS cells, a co-transfection of NgR1 and 
p75NTR could not recapitulate the downstream event of RhoA activation by MAI. A 
signaling component (or components) is apparently missing. LINGO-1 (LRR and Ig 
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domain-containing, Nogo receptor interacting protein) was latter found to interact with 
NgR1 and functions as the additional missing component required for NgR1/p75NTR 
signaling in non-neuronal cells (Mi et al., 2004). 
LINGO-1, identified based on his homology to the guidance molecule Slit (Mi 
et al., 2004), is a 614 amino-acid, type I transmembrane protein. LINGO-1 has 12 
leucine-rich repeat (LRR) motifs flanked by the LRRNT and LRRCT domains, 
followed by one immunoglobulin IgC2 domain, a transmembrane domain and a short 
cytoplasmic tail (Fig 1-2).  Its cytoplasmic tail has a canonical EGF receptor-like 
tyrosine phosphorylation site (which appears to be functionally critical for LINGO-1-
associated signaling). Three other LINGO family members can be identified from the 
database. They are much lower in transcript abundance compared to LINGO-1 in CNS 
and are ubiquitously expressed (Mi et al., 2004). LINGO-1 is highly conserved, with 
human and mouse orthologs sharing 99.5% identity. Its cytoplasmic tail is completely 
identical across some mammalian species such as human, mouse and monkey. LINGO-
1 was also previously identified in silico by a gene content analysis of the chromosomal 
15q24-q26 region which was suspected to encode anxiety disorder related genes, and 
was named LRRN6A (Leucine-rich repeat neuronal 6A) (Carim-Todd et al., 2003). The 
gene encoded protein is named LERN1 (Leucine-rich repeat neuronal protein 1). Some 
of its paralog genes were also identified and named LRRN6B (LINGO-3), LRRN6C 
(LINGO-2) (see Fig 1-1). Both groups of researchers showed that LINGO-1 is highly 
expressed in brain but not detected in non- neural tissues using northern blot (Carim-
Todd et al., 2003; Mi et al., 2004). It is widely distributed in different regions of the 
brain and spinal cord and exhibits a rostral to caudal gradient (Mi et al., 2004). 
Chapter1                                                                                                         Introduction 
 21
In non-neuronal COS cells, co-expression of human NgR1, p75NTR and LINGO-
1 conferred responsiveness to the myelin-associated inhibitor such as NgR1 ligand 
OMgp, as demonstrated by the latter's ability to activate RhoA. Overexpression of 
LINGO-1 in neurons enhanced responsiveness to myelin-associated inhibitors, while 
expression of a dominant-negative LINGO-1 construct (LINGO-1-DN, with a truncated 
cytoplasmic tail) attenuated myelin inhibition of neurite outgrowth. In addition, 
exogenously added LINGO-1-Fc fusion protein also attenuated outgrowth inhibition, 
presumably by disrupting the ternary NgR1/p75NTR/LINGO-1 membrane complex. 
LINGO-1 also interacts with and mediate the action of TAJ/TROY (Park et al., 2005; 
Shao et al., 2005), which is more ubiquitously expressed in the brain than p75NTR.  
LINGO-1 is also found to be expressed in oligodendrocytes and has a role in 
modulating oligodendrocyte differentiation and myelination (Mi et al., 2005). 
Overexpression of LINGO-1 activates RhoA and inhibits oligodendrocyte 
differentiation and myelination, and attenuation of LINGO-1 reduced RhoA activity. 
Accordingly, LINGO-1-DN transfection, LINGO-1 knockdown by RNA interference 
(RNAi) introduced via a lentivirus vector, or LINGO-1-Fc all enhanced differentiation 
and increased myelination of primary oligodendrocytes in culture. Oligodendrocyte–
neuron co-cultures treated with LINGO-1-Fc formed well-developed myelinated axons 
in vitro, with distinctly defined nodes and internodes. Analysis of LINGO-1 knockout 
mice revealed that spinal cords from P1 (postnatal day 1) newborns have more 
myelinated axon fibers compared to wild type littermates, and oligodendroglia cultured 
from these mice had a larger percentage of mature oligodendrocytes than wild type. In 
disease model such as Myelin oligodendrocyte glycoprotein (MOG)-induced murine 
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experimental autoimmune encephalomyelitis (EAE), treatment with LINGO-1 
antagonist promotes spinal cord remyelination and axonal integrity, a phenotype which 
is also exhibited by the Lingo-1 knockout mice (Mi et al., 2007). In all, the above results 
illustrate multiple functions for LINGO-1 in the CNS.  
 
1.3.7 The intracellular signaling pathway from NgR1 
Small GTPases of the Rho family such as RhoA, Rac1 and Cdc42 (cell division 
cycle 42) are important regulators of the actin cytoskeleton. RhoA activation has been 
shown to correlate with growth cone collapse and axon guidance repulsion (Hall 1998). 
RhoA can be directly activated by MAIs (Winton et al., 2002, Yamashita and Tohyama, 
2003). Further investigation shows that the engagement of neuronal NgR1-p75NTR and 
LINGO-1 by MAI mediates neurite growth inhibition, resulting in the activation of 
RhoA and suppression of Rac 1 (Niederost et al., 2002, Fig 1-3). The NgR1-
p75NTR/LINGO-1 receptor complex presumably activates the trimeric G protein Gi and 
the downstream phospholipase C (PLC)-protein kinase C (PKC)/Inositol 1, 4, 5 –
triphosphate (IP3) pathways (Hasegawa et al., 2004). PKC is activated by both PLC 
generated diacylglycerol and the elevation of growth cone cytoplasmic Ca2+ (a result of 
IP3-induced Ca2+ release from internal stores). PKC appears to be important for Rho 
activation, because PKC inhibitors attenuate MAG’s ability to inhibit neurite growth 
(Sivasankaran et al., 2004) and may in some cases enhance neurite growth (Hasegawa 
et al., 2004). 
The PKC-dependent cleavage of p75NTR has been shown by Filbin’s laboratory 
to be induced by MAG binding to cerebellar granule neurons, and is necessary for Rho 
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activation (Domeniconi et al., 2005). p75NTR was known to undergo ectodomain 
shedding and regulated intramembrane proteolysis (RIP) – an α-secretase-mediated 
process that generates an extracellular domain (ECD) and a C-terminal motif. The latter 
is further cleaved by the γ-secretase complex to generate an intracellular domain (ICD) 
(Jung et al., 2003; Kanning 2003). In the cell, Rho is kept inactive in the cytosolic pool 
by its binding to the Rho GDP dissociation inhibitor (Rho-GDI) (Olofsson 1999). Upon 
cleavage, the intracellular domain (ICD) of p75NTR displaces Rho-GDI from Rho. 
p75NTR activates Rho, presumably by acting as a displacement factor (the p75NTR-ICD) 
that releases Rho from Rho-GDI, which leads to RhoA activation subsequently by its 
guanine nucleotide exchange factors (Yamashita and Tohyama, 2003). This recent 
finding provided some possible resolution to the previous paradoxical observation that 
endogenous p75NTR is in complex with Rho-RhoGDI, and that MAG/Nogo-66 binding 
appears to strengthened existing p75NTR–Rho-RhoGDI complexes rather than 
weakening it. Thus, upon cleavage, the ICD fragment of p75NTR, unlike full-length 
p75NTR, could perturb RhoGDI’s ability to inhibit GTP-GDP exchange on Rho, thereby 
resulting in its dissociation from RhoGDI.  
By systematically screening libraries of small molecules for their ability to 
promote outgrowth on inhibitory substrates, He and colleagues found that suppressing 
the kinase function of EGFR and PKC blocks the activities of both myelin inhibitors 
and chondroitin sulfate proteoglycans in inhibiting neurite outgrowth (Koprivica et al., 
2005). Pharmacological inhibition of conventional PKC isoforms attenuated outgrowth 
inhibition and RhoA activation by myelin-associated inhibitors. Similarly, EGFR 
activation is also required by both inhibitory influences. Although a direct interaction 
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with NgR1 components was not detected, EGFR is phosphorylated and then 
transactivated by calcium influx. 
In growth cone turning assays, p75NTR and NgR1 are also found to be 
responsible for the intracellular activation of Ca2+ that resulted in growth cone turning 
(Wong ST et al., 2002). However, the effect of MAG-induced Ca2+ on growth cone 
behavior is complex. It may mediate growth cone repulsion or attraction depending on 
the exact concentration of Ca2+ elicited (Henley et al., 2004). This effect is modulated 
by intracellular 3'-5' cyclic adenosine monophosphate (cAMP) (Henley et al., 2004; 
Song et al., 1998). Both Ca2+ and cAMP regulate the Rho activity. It should be noted 
that neurite growth inhibition and growth cone repulsion and attraction are experimental 
phenomena. Different experimental paradigms have different emphasis in terms of 
parameters measured. On the whole it would seem that the same set of pathways and 
components are engaged, but there may be subtle differences. 
 
1.4 Rationale for current work 
Leucine-rich repeat (LRR) is a well known protein-protein interaction domain. 
Recent finding suggests the existence of a large group of these LRR proteins that are 
enriched in the central nervous system, and may play very important roles during 
development and in adult brain. 
We have noted an emerging group of type I membrane proteins with LRR 
repeats and a domain usually associated with cell adhesion molecules. AMIGO is one of 
these proteins with LRR and Ig domains, and is almost exclusively expressed in the 
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CNS. We have raised a specific antibody against AMIGO and examined the expression 
and localization of AMIGO in brain sections at the cellular level. In order to gain a 
better understanding of functional domains of AMIGO, we generated AMIGO-LRR and 
AMIGO-Ig mutant constructs with one of its functional domain deleted. The 
localization and activity of these mutants were studied in neuroblastoma cells and 
primary cortical neurons. Furthermore, the effect of double-stranded small interfering 
RNA (siRNA) knockdown of AMIGO on cortical neuron neurite growth was also 
examined. These and other related works are described in Chapter 3. 
LRR-containing protein Nogo-66 Receptor (NgR1) is famous as a receptor for 
several myelin-associated inhibitors (MAI) and inhibits the axonal regeneration after 
injury. The recently identified NgR1 homologue, NgR2 is able to bind to one of NgR1’s 
ligand-MAG, which implies that it could be a potential neurite outgrowth inhibitor 
receptor in CNS. We have generated a specific antibody against NgR2, examined the 
brain tissue distribution of NgR2, and studied its interaction with the known NgR1 co-
receptors LINGO-1 and p75NTR. Works related to NgR2 is described in Chapter 4. 
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2.1 General Materials and reagents 
2.1.1 General materials and reagents 
Most chemicals and reagents were purchased from Sigma-Aldrich Pte. Ltd. 
(Singapore) and Bio-Rad Laboratories (Hercules, CS, USA) unless indicated otherwise. 
All restriction enzymes were purchased from either Promega (Madison, WI, USA) or 
New England Biolabs (Ipswich, UK). Protein molecular size markers and 
polyacrylamide solution (Acryl: Bisacylamide = 29:1) was purchased from BioRad. The 
horseradish peroxidase (HRP)-conjugated goat anti-mouse and goat anti-rabbit IgG 
antibodies were from Pierce Chemical Co. (Rockford, IL, USA). HRP-conjugated 
donkey anti-goat, donkey anti-human IgG antibodies and donkey/goat anti rabbit IgG 
conjugated with Fluorescein isothiocyanate (FITC)/Texas red, donkey/goat anti mouse 
IgG conjugated with FITC/Texas red, donkey anti human IgG conjugated with FITC 
were from Jackson Immunoresearch Inc. (West Grove, PA, USA). E.coli strains DH5α 
and BL21 (DE3) were purchased from Invitrogen Corp. (Carlsbad, CA, USA). Plasmid 
vectors pGEX4T-1, pCIneo, pcDNA4B were from GE Healthcare Bio-sciences Corp. 
(Piscataway, NJ, USA), Promega and Invitrogen Corp., respectively. DNA sequences 
were analyzed by Research Biolabs (Singapore). 
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2.2 Plasmids construction 
2.2.1 Expression constructs 
Expression sequence tags (EST) of NgR2 (IMAGE: 1926673) was obtained 
from Invitrogen Corp.. These were subcloned by the polymerase chain reactions (PCR) 
into pCIneo and other expression vectors. The primers (from Research Biolabs or 1st. 
Base (Singapore)) used in all plasmid constructs are listed in Table2-1. Recombinant 
DNA methodologies are detailed in section 2.4.2 below. Full length NgR2 was obtained 
by joining a DNA fragment generated by PCR from HeLa genomic DNA, and ligated 
with the partial NgR2 EST fragment, and subcloned into the pCIneo vector. To 
generated myc epitope tagged forms of the constructs, a PCR-generated NgR2 signal 
peptide sequence (SS) was first inserted into pDmyc (a modified pCIneo vector in 
which a tandem myc epitope sequence were inserted at the Nhe1 cloning sites) and the 
sequence orientation was checked by Pvu II restriction enzyme (RE) digestion and 
sequencing. This generates the pCIneo-SS-myc vector. The rest of NgR2 gene was then 
subcloned inserted after the myc sequence to generate the construct of pCIneo-SS-myc-
NgR2 (myc-NgR2). The NgR1 myc-tagged construct pCIneo-SS-myc-NgR1 (myc-
NgR1) was likewise made by inserting the coding region of NgR1 into pCIneo-SS-myc. 
EST for NgR3 (IMAGE: 536860) was obtained from Invitrogen Corp. and subcloned 








Xho I Sal IEcoR INhe I Nhe I
NgR2SS
 
Figure 2-1 A schematic diagram showing the construct myc-NgR2 in pCIneo based 
on the modified vector pCIneo-SS-myc.  
NgR2 EST fragment (EcoR1 to Xho1) is ligated together with a DNA fragment generated by 
PCR from HeLa genomic DNA (Xho1 to Sal 1). 
 
PCR products of AMIGO LRR domain (LRR), Ig domain (Ig) and 
transmembrane domain with cytosolic C-terminal domain (TM+CT) were generated 
separately by PCR from the IMAGE EST clone 5725643. LRR domain or Ig domain 
was then ligated together with the (TM+CT) domain into pBluescriptKS (pBSK) vector 
(Strategene). The inserts were then drop-out from pBSK and inserted into pCIneo-C-
myc vector (A modified pCIneo vector with myc epitopes inserted at 3’ end of the 
multiple cloning site) to produce the respective C-terminal myc-tagged AMIGO mutant 
constructs (AMIGO-LRR and AMIGO-Ig).  
LINGO-1 and the mutant LINGO-1-DN were generated directly by PCR from 
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Table 2-1 Oligonucleotide primers used in the generation of expression constructs.  
Restriction enzymes (RE) sites are underlined. 
Name Sequence RE 
AMIGO-N-t-SS-F  CCC GCTAGC ACC ATG CAC CCC CAC CGT 
GAC CC 
Nhe1 
AMIGO-N-t-SS-R CCG GAATTC GGC TCG GCC AGC TCT GGC 
C 
EcoR1 
AMIGO-TM-F CCA AAGCTT GAC ACC CTC AAC ACA GCC 
TAT ACC ACC 
HindIII 
AMIGO-C-t-R GAA GTCGAC CAC CAC AAT GGG CGT ATC 
AGA GGA G 
Sal1 
AMIGO-Ig+TM-F CTA GAATTC CAC CTG GGT GAC ACC TTG 
ATC ATC AGG 
EcoR1 
AMIGO-C-t-R GAA GTCGAC CAC CAC AAT GGG CGT ATC 














GC GTCGAC TCA GCC CTT GCC CCG GCT 
CCA GAG AAA CAG 
Sal1  
NgR3-F1-m CC GAATTC AAG ATG CTT CGC AAA GGG 
TGC 
EcoR1 
NgR3-R1-m CGCGGCCG C TCA GCG GAG AGT GAC TGC Not1 
NgR2 SS-F (h)-
before myc 
C GCTAGC GAG CAT CGA GAC AAG ATG 
CTG C  
Nhe1 
NgR2 SS-R (h) 
(before myc) 
GAG GCTAGC GCA GCT GGG GGC CGC CAG   Nhe1 
NgR2-After SS-F 
(after myc) 
CG GAATTC ACC CAT GCT CTG CAC CTG 
CTA GTC 
EcoR1 





CG GAATTC ATG CCC AGG TGC CTG CGT 
ATG CTA C 
EcoR1 
NgR1-R C GTCGAC TCA GCA GGG CCC AAG CAC 
TGT CC 
Sal1 
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2.3 Mammalian cell culture 
2.3.1 Cell culture 
Human embryonic kidney cells (HEK293) and human neuroblastoma SHSY5Y 
cell lines were purchased from ATCC. These are maintained in Roswell Park Memorial 
Institute (RPMI) medium with 10% Fetal Bovine Serum (FBS) (HyClone Laboratories 
Inc, Logan, Utah, USA) and a penicillin-streptomycin (pen/strep) antibiotics mixture 
(Gibco). The mouse neuroblastoma cell line Neuro2A was kindly provided by Prof Too 
Heng Phon and Dr Yoong Li Foong (Department of Biochemistry, NUS). This line is 
maintained in high glucose Dulbeco’s Modified Eagle’s Medium (DMEM) (Hyclone) 
with 10% FBS (Hyclone) and pen/strep antibiotics mixture. Neuro2A cells were 
induced to differentiate and exhibit neurite extension morphology by incubating in 
DMEM medium with reduced (0.5%) FBS and 10μM retinoic acid (RA, Sigma) for 3 
days. 
2.3.2 Transfection and selection of stable clones 
Two types of transfection reagents were used depending on cell types and 
confluency. Effectene (Qiagen) was used largely for transfecting cells with 40-70% 
confluency according to manufacturer’s instruction. Lipofectamine 2000 (Invitrogen) 
was generally used for cells with more than 90% confluency. Briefly, 10 μg of DNA 
and 25 μl Lipofectamine 2000 (Invitrogen) were separately diluted in 1.5ml of Opti-
MEM (Invitrogen), mixed together and incubated for 20 min. The DNA-Lipofectamine 
2000 mixture was then added to cells grown in 90 mm dishes in normal culture medium 
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and incubated in a humidified CO2 incubator at 37 ˚C for 3 hr. The transfection medium 
was then replaced with fresh culture medium and incubated for a further 24 hr.  
The expression vectors and constructs carry a neomycin resistance marker and 
transfectants are selected with final concentration of 0.8 mg/ml of gentamycin sulfate 
(G418) (Promega) over a period of about two months. G418 resistant cell colonies are 
picked and propagated. Expression of the respective genes and mutants are determined 
by reverse-transcription (RT)-PCR, immunoflurescence as well as Western blot analysis 
(section 1.3.5). Primers used for RT-PCR analysis are listed below. 
 




LINGO-1-RT-F AGA GAC ATG CGA TTG GTG A 
LINGO-1-RT-R AGA GAT GTA GAC GAG GTC ATT 
NgR1-RT-F-(mr) GATG AGG AGG GCG TCC TCC GGA GAA AG 
NgR1-RT-R-(mr) GCT CCA GGA GGG TCA GAC CAG TGA AG  
NgR2-RT-F-(mr) GATG CTG CCC GGG CTC CGG CGC CTG 
NgR2-RT-R GAT GGT GGA GAG GTT GTT GGA GAA GAG 
p75NTR-RT-F CAG ATG AAG CCA ACC ACG TG 
p75NTR-RT-R GCT GTT CCA TCT CTT GAA AGC AA 
TROY-RT-F AGT ATC ACC GGG ACT CAG 
TROY-RT-R TGG CCG CCA CTG GAA T 
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2.3.3 Primary cortical neuron culture  
C57/ BL6 mice fetuses at embryonic day 16 (E16) were used in culturing of 
primary cortical neurons. The pregnant mother mice were deeply anesthetized by 
intraperitoneal injection with 0.2ml of a ketamine and xylaxine mixture, and euthanized 
by cervical dislocation. The abdomen area was cleaned with 70% ethanol and open. The 
amnia were carefully removed and immersed in harvest medium (hank’s solution 
without Ca2+ and Mg2+ (Gibco), with 10mM HEPES (Sigma) and antibiotics. The 
embryos were then freed of the amnia and decapitated, and the cerebral hemispheres 
were carefully removed by gently scooping out with forceps. The meninges covering on 
the cerebral were then removed with forceps. The cortices were placed into a 15 ml 
tube. 0.2ml of 2.5% trypsin and 1% DNase tryptic digest solution were added, and the 
suspension incubated at 37ºC for 15 min. 0.2 ml FBS were added to stop trypsinization. 
The supernatant were carefully removed and 2ml of plating medium (Minimum Eagle’s 
medium (MEM) (Invitrogen) with 0.05% NaHCO3, 1% sodium pyruvate, 6% glucose, 
15% FBS and antibiotics) and suspended by repeated pipetting. Cell were then counted 
and plated at a density of 0.67-1 X 105 cells /cm2 in plating medium on poly-L-lysine 
coated dishes or 12mm round coverslips (for immunofluorescence analysis). Plated 
cells were incubated for 24 h before changing to maintaining medium (Neurobasal 
medium with 2% B-27 and 5% of L-glutamine (Invitrogen Corp.)). 
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2.3.4 Primary glia culture 
Newborn (postnatal day 1) old pups of Sprague Dawley rats or C57/BL6 mice 
were cleaned with 70% ethanol, anesthetized on ice and decapitated. The brains were 
then removed and immersed in collection medium (DMEM/F12 with pen/strap 
antibiotics) (Gibco). The meninges-free whole brains were cut into small cubes and 
digested with 0.1% trypsin in versene (PBS/EDTA 0.53 mM) for 30 min at 37 ˚C. The 
digestion was then inhibited by adding culture medium (DMEM/F12 medium with 10% 
of FBS). Cells were suspended by repeated pipetting with a Pasteur glass pipette then 
filtered through a 40 μm sieve.  The cells were then seeded at approximately 1 to 2 
brains per 75-cm2 flasks and cultured with culture medium. Cultures were incubated for 
5-7 days and were then shaken with an orbital shaker at 200 r.p.m (round per min) 
overnight. The supernatant containing oligodendrocytes were then plated into 60 mm 
dishes with a few PLL coated coverslips. The remaining cells on the 75-cm2 flask are 
mainly astrocytes which were then trypsinized and plated into 60 mm dishes with PLL 
coated coverslips. 
 
2.3.5 Assessment of Neurite outgrowth 
After 4-8 days in vitro (DIV), primary cortical neurons grown on 12 mm 
coverslips (in 24 well plates) were transfected with 1 μg of DNA (or 0.8 μg of interest 
DNA with 0.2 μg of Enhanced Green Fluorescence Protein (EGFP) expression plasmid) 
with 2.5 μl of Lipofectamine 2000. Cells were then fixed and prepared for 
immunofluorescence analysis as described in section 2.3.6. The extent of dendrite 
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growth was determined by the length of the microtubule-associated protein 2 (MAP2) 
positive dendrites. Cells were classified based on their longest neurites (Fig 3-8 A) or 
dendrites (Fig 3-10 C). Experiments were typically conducted in triplicates in three 
separate experiments. Proportion of cells with different extent of neurite growth was 
calculated as percentage of total cells counted. Statistical analysis and comparison 
between the populations were made using 2-tailed hypothesis testing (ANOVA), with 
the null hypothesis that there is no difference between two populations in question. 
 
2.3.6 AMIGO silencing in cortical neurons 
AMIGO knockdown was performed using a 27-mer “dicer ready” double-
stranded small interfering RNA (siRNA) (1st-base Pte Ltd., Singapore). The following 





Primary cortical neurons plated in 1.37 X 105 cells /cm2 in 6-well plates were 
transfected with 300 pmole (5 μg) of AMIGO siRNAs or scrambled siRNA using 
Lipofectamine 2000 and incubated for 24 hr. The transfection media were then replaced 
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with fresh culture medium and the neurons were further incubated for another 30 hr to 
allow protein turnover and effective silencing.  
 
2.3.7 Western blot, immunofluorescence and immunohistochemistry 
Proteins resolved by SDS-polyacrylamide gels were electroblotted onto 
nitrocellulose membranes (Hybond-C extra, GE healthcare). The membrane was 
blocked with blocking buffer (5% milk in Phosphate Buffered Saline (PBS)) overnight 
at 4˚C, or 1hr at room temperature with shaking. Primary antibody was then added at a 
final concentration of 1-5 μg/ml in blocking buffer for 1 hr, followed by HRP-
conjugated secondary antibody at a concentration of 0.1 μg/ml for 1 hr. The membranes 
are washed extensively (3 washes, 10 min each) with washing buffer (0.05% Tween 20 
in PBS) after each antibody incubation. Chemiluminescence reagents (Pierce) diluted 
1:1 with water were then added to the membrane, followed by incubation for 5 min with 
shaking. Finally, the membrane was exposed to an X-ray film (Kodak, Singapore Pte. 
Ltd.) for varying lengths of time to obtain the appropriate signal intensity. Exposed 
films were then developed using a Kodak X-OMAT 200 processor (Kodak, Singapore 
Pte. Ltd.). 
For immunofluorescence analysis, cells or neurons plated on 12 mm coverslips 
were fixed by 4% paraformaldehyde in PBS for 30 min. The coverslips were then 
washed (once with PBS, twice with PBS/100 mM NH4Cl and once more with PBS, 3 
min each wash) and permeabilized with 0.1% saponin (Sigma) in PBS for 15 min. 
Permeabilized cells were incubated with blocking buffer (2% BSA, 5%FBS in PBS) for 
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30 min. Coverslips were then inverted (with cell side down) onto a drop (35μl) of 
primary antibody diluted in blocking buffer for 1 hr, followed by secondary antibody 
conjugated to fluorophores (FITC or Texas Red) for 1 hr. Coverslips were washed with 
0.1% saponin in PBS (3 X 3 min each wash) after each antibody incubation. The 
coverslips were then mounted onto glass slides using a glycerol-based mounting 
medium, Vectashield (Vector Laboratories). The edge of coverslips was sealed with nail 
polish prior to microscopy. 
For immunohistochemistry (IHC), mice were perfused with 4% 
paraformaldehyde in phosphate buffer. Brain and spinal cord are removed and soaked in 
30 % sucrose solution for 48 hr. Tissues are embedded in Optimal Cutting Temperature 
(OCT) embedding medium (Tissue-tek) and cryosectioned into 20 μm sections placed 
on PLL coated glass slides. Sections were permeabilized by 0.2% Triton X 100 for 1 hr 
and washed as above (1X PBS, 2X PBS/100mM NH4Cl and 1X PBS, 5 min each wash). 
The sections were then incubated with 70-100 μl of IHC blocking buffer (10% FBS and 
5% BSA in PBS) for 1 hr, followed by primary antibodies diluted in blocking buffer at 
room temperature for 4 hr, or at 4˚C overnight. The sections were then washed in PBS 
for 5 min (3 times), followed by incubation with secondary antibody conjugated to 
respective fluorophore for 1 hr. The DNA dye Hoechst 33342 was typically used as a 
nuclear counterstain. Where applicable, staining was done by simply incorporating the 
dye (20,000 fold diluted) into PBS and the sections were incubated for 3 min in it. The 
sections were then washed thoroughly (PBS, 5 min for 4 times). The section was then 
covered by a drop of Vectashield, followed by a glass coverslip. The edge of the 
coverslips was sealed by nail polish to prevent evaporation of the mounting medium. 
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2.3.8 Antibody blocking 
1 μg of purified NgR2 or AMIGO antibodies from rabbits (see section 2.5) and 
20 μg NgR2-GST or AMIGO-GST antigens were mixed and incubate with rolling for 2 
hrs at 4˚C. This mixture was then diluted with IHC blocking buffer (see section 2.3.6) 
and used in immunohistochemistry analysis. 
 
2.3.9 Confocal microscopy 
The cells and sections are viewed with an Axiophot microscope (Carl Zeiss, 
Oberkochen, Germany) equipped with a Carl Zeiss 510 confocal imaging system. 
Images are collected in separate z sections and final images presented are typically from 
collapsed z-stacks. Montages and labeling of images and performed using Adobe 




Cells manipulated by transfections were harvested after 24 hr and lysed in 1ml 
of lysis buffer and incubated with rolling for 30 min at 4˚C followed by centrifugation 
at 15,000g for 15 min. The supernatants were incubated with antibodies overnight at 
4˚C and then incubated with protein-A or protein-G sepharose beads (GE healthcare) 
for 2 hr. The beads were washed three times with lysis buffer and boiled in Laemmli 
sample buffer to elute bound protein, which are subsequently analyzed by Western blot. 
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2.3.11 PI-PLC treatment  
Cells stably expressing the GPI-linked proteins NgR1, NgR2 were grown to 50-
70% confluency. Cells were rinsed with RPMI or DMEM basal medium and then 
incubated with phosphatidylinositol-specific phospholipase C (PI-PLC) (1U/ml) in 
basal medium in the 37 ºC-incubator for 2 hr. The cells were then washed thoroughly 
with basal medium, fixed in 4% paraformaldehyde for 20 min, and subjected to 
immunofluorescence analysis. 
2.4 Generation of Recombinant DNA and proteins 
2.4.1 Strains and Growth conditions 
E. coli strains DH5α and BL21(DE3) were either cultured in LB (Luria-Bertani) 
broth (1% bacto-tryptone, 0.5% bacto-yeast extract, 1% NaCl, pH 7.0) or maintained on 
LB agar plates (LB containing 2% bacto-agar) at 37°C. When recombinant plasmid-
containing transformants were cultured, the LB media/agar was supplemented with   
100 μg/ml of ampicillin. 
2.4.2 Recombinant DNA methods 
 
General DNA manipulations were performed essentially as described by 
Sambrook et al. (1989). Polymerase chain reaction (PCR) was carried out with pfu 
DNA polymerase (Promega) to amplify the desired DNA fragments. The DNA 
fragments were resolved using horizontal agarose gels (0.8-2.0 %) containing 50 μg/ml 
2.4.2.1  Recombinant plasmid construction
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ethidium bromide in Tris-acetate-EDTA buffer (45 mM Tris-acetate, 1 mM EDTA, 
TAE), and purified using the QIAquick Gel Extraction Kit (Qiagen) according to the 
manufacturer’s instruction. Both the plasmid vectors and purified PCR products were 
digested by the respective restriction enzymes (RE) as listed in Table2-1.  RE digests 
were performed using the appropriate buffers supplied by the manufacturers. RE 
digested vectors were treated with Calf Intestinal Alkaline Phosphatase (CIP) at 37˚C 
for 45 min. Ligation was typically performed using T4 DNA ligase (New English 
Biolabs) at 16˚C overnight. 
Plasmid DNA preparation was done using the mini-plasmid preparation 
(miniprep) and maxi-plasmid preparation (maxiprep) kits (Promega). The isolated 
recombinant plasmids were subjected to diagnostic RE digestions and resolved using 
agarose gel electrophoresis with ethidium bromide incorporated. The gel is then 
photograph under UV light using a Kodak gel documentation system (Research 
Biolabs). 
 
For bacterial transformation, recombinant plasmid DNA or ligation mixture was 
added to 150 μl of the competent cells and incubated on ice for 30 min. This was 
followed by a heat shock step at 42°C for 2 min, and the tubes were then chilled on ice 
again for 1 min. 1 ml of SOC medium (2% bacto tryptone, 0.55% bacto yeast extract, 
10 mM NaCl, 10 mM KCl, 10 mM MgCl, 10mM MgSO4, 20mM glucose) was added 
and the culture was incubated at 37°C for 1 hr before being plated onto LB agar plates 
with 100 μg/ml ampicillin. 
2.4.2.2 Transformation of E. coli cells
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2.4.3 Recombinant protein preparation and analysis 
 
To make glutathione S-transferase (GST) fusion proteins, the appropriate DNA 
fragments were generated by PCR and cloned in-frame into the bacterial GST 
expression vector pGEX4T-1 Amplified clones were analyzed for inserts by diagnostic 
disgests and insert sequences were verified by DNA sequencing analysis. The primers 
used in making recombinant protein expressing constructs in E. coli are listed in Table 
2-3 below. 
Table 2-3 Oligonucleotide primers used in making recombinant protein expressing 
constructs in E. coli. Restriction enzymes (RE) sites are underlined. 
 
Name Sequence RE 
NgR2-GST-
ab-F 
GCAG GGATCC CCC GCG GCA CCC ACG CGG  BamH1 
NgR2-GST-
ab-R 





GTG GAATTC CGC TGC TGG TGC CGG GGT G EcoR1 
AMIGO-
GST-R 
GAG CTCGAG TCA CAC CAC AAT GGG CGT 
ATC AGA G 
Xho1 
 
For large scale fusion protein preparation, 200 ml of LB/Amp inoculated with 
50 μl of seed bacteria culture was grown overnight.  The overnight culture was topped 
up with 600 ml fresh LB/Amp medium and grew to a density of OD600 0.5-1.0. The 
culture was induced using 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) and 
incubated at room temperature overnight or at 37°C for 4 hr. Cells were collected by 
centrifugation at 2,500g and resuspended in cold PBS with 0.1 mM of the protease 
inhibitor phenylmethylsulfonyl fluoride (PMSF). The suspensions were sonicated on ice 
2.4.3.1  Fusion protein production in E.coli, Recombinant protein elution and dialysis
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and the lysates were centrifuged at 20,000g for 45 min. The supernatants were then 
incubated with rolling with glutathione agarose beads (Pharmacia) for 2 hr at 4C.  
Beads were transferred to disposable columns (Bio-Rad) and washed 
extensively with PBS. Elution of 5 fractions of 1 ml is done by incubating with elution 
buffer (10 mM glutathione, 50 mM Tris-HCI pH 8.0). The concentration of each eluent 
was assessed by SDS-PAGE followed by Commassie brilliant blue (Bio-Rad) staining. 
 
2.4.3.2 Fusion protein production in Mammalian Cells 
The plasmid construct pECE-MAG-Fc expressing MAG-Fc was a generous gift 
from Dr Eyleen Goh (John’s Hopkins University, USA). The human immunoglobulin 
constant region (Fc) were retrieved by Xho1/Xba1 digest from pECE and inserted into 
pCIneo to generate pCIneo-Fc vector. MAG ectodomain from pECE construct was then 
exerted out and inserted at Nhe1/Xho1 site. pCIneo-MAG-Fc is thus constructed and a 
HEK293 cell line stably expressing is obtained (see methods in section 2.3.2).  
 
2.5 Rabbit polyclonal antibody preparation  
500 μg of antigen (bacterial recombinant protein) was diluted into 2 ml volumes 
with sterile PBS, and homogenized with 2 ml of Freund’s adjuvant (Sigma) to form a 
stable emulsion. This was then injected subcutaneously into four separate subcutaneous 
spots of the rabbit. The first immunization was carried out with Complete Freund’s 
adjuvant and subsequent boosters were done with Incomplete Freund’s adjuvant. Test 
bleeds were typically done after the 4th or 5th booster injection, and animals with a 
Chapter 2                                                                                        Materials and methods 
 43
positive response received an additional booster each time prior to blood harvest. 9 days 
after a booster injection, 10-50 ml of blood was collected from the rabbits’ central ear 
artery with an infusion needle and allowed to clot at 4˚C overnight. Serum was 
harvested after centrifugation for 20 min at 1,800g at 4˚C. 
To affinity purify antigen-specific antibodies, 400 μg of the fusion proteins was 
electroblotted onto nitrocellulose membrane (Hybond-C extra, GE healthcare) after 
SDS-PAGE. The protein band on membrane was visualized by reversible staining with 
Ponceau S solution (2% Ponceau S in 5% acetic acid) staining. This band was then 
excised and washed with PBS. The membrane strip was then incubated with diluted 
rabbit serum (1:1 dilution in PBS) at 4 ˚C overnight with rolling. The strip was then 
washed, cut into tiny pieces and placed into an eppendorf tube (1.5 ml). 300 μl of IgG 
elution buffer (Tris-HCl, Glycine pH 3.0) (Pierce) was added. The tube was vortexed 
and then centrifuged at 16,100g for 30 seconds. The supernatant eluents were 
transferred to a new tube and neutralized by the addition of 1 M Tris-HCl pH 8.0. It was 
then centrifuged for 5 min at 16,100g at 4 ˚C to remove any insoluble materials, 
aliquoted, and stored at -20 ˚C until further use. 
 
 










3 RESULTS: AMIGO IS EXPRESSED IN MULTIPLE 
BRAIN CELL TYPES AND MAY REGULATE 
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3.1 AMIGO is expressed in multiple brain cell types 
3.1.1 Expression of AMIGO in rodent brain 
We started out with an interest in assessing the function of LRR-containing 
proteins in the brain. We have noted that AMIGO’s domain structure and known 
neuronal expression may hint at its role in regulating CNS neurite growth. To create 
a handle for examining endogenous AMIGO, we raised polyclonal antibodies 
against the cytoplasmic tail of AMIGO in rabbits. Based on cDNA coding region 
length, the predicted size of AMIGO protein is around 56 kDa. However, affinity-
purified rabbit anti-AMIGO antibody detected, by Western blot analysis, a doublet 
band of 70 kDa and 80 kDa in AMIGO-myc expression construct-transfected 
Neuro2A cells. A band 75 kDa in size is also detected in both mouse and rat brain 
lysates (Fig 3-1 A). A Western immunoblot survey of several developmental stages 
of mouse brain revealed that AMIGO is expressed from embryonic Day 14 (E14) 
and the expression is gradually elevated until birth. The expression level is slightly 
decreased at about one week after birth, increased again, and remained high in 
adulthood (Fig 3-1 B). AMIGO is not dramatically down-regulated in the one week-
old mouse compared to rat, as reported previously (Kuja-Panula et al. 2003). The 
reason behind these observed differences between mice and rats AMIGO expression 
pattern during development is unclear at the moment. 
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Figure 3-1  Characterization of an antibody raised against AMIGO and 
developmental expression survey of AMIGO in mouse brain. 
A: Western blotting with anti-AMIGO antibody. pCIneo vector (vector control) and 
expression constructs of full length AMIGO-myc, were transfected into Neuro2A cells. Cell 
lysates together with adult mouse and rat brain lysates (4 µg per lane) were subjected to 
SDS-PAGE and western blotted with AMIGO antibody raised against its intracellular 
domain in rabbit. B: AMIGO expression during mouse brain development, E: embryonic 
day; NB, new born; W, postnatal week. The γ-tubulin (Tubulin) blot showed equivalent 




Previous immunohistochemical localization of AMIGO protein in the brain 
revealed that it is enriched in nerve fibers and tracts (Kuja-Panula et al., 2003). 
Using our antibodies, we performed immunofluorescence analysis of mice brain 
cryosections at higher magnifications (zoomed into cellular levels) and noted 
AMIGO staining patterns that are more highly resolved and distinct from that 
previously reported. AMIGO is present in a wide variety of brain neurons in 
different areas of the adult brain and spinal cord. Besides strong neuronal cell body 
staining, we noticed that AMIGO staining is stronger in neuronal dendrites 
(Microtubule Associated Protein 2 (MAP2)-positive fibers) rather than axons (Fig 3-
2 A). This dendritic staining is particularly well illustrated by the hippocampal 
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neurons (Fig 3-2 B) and the elaborate dendritic tree of the cerebellar Purkinje 
neurons (Fig 3-2 C). However, no apparent staining was observed in the axons in 
these regions. In the brain stem medulla region, AMIGO labels the neuron cell 
bodies strongly, but the staining do not co-localize with brain specific βIII tubulin 
(TuJ) (Fig 3-2 D). This suggests that AMIGO is not localized to axons of the brain 
stem region. However, some weak co-staining with TuJ is obtained in spinal cord 
white matters (Fig 3-2 E). In the hippocampus, the expression levels of AMIGO 
increase in a gradient from the dentate gyrus to the subiculum region (Fig 3-3).  
 
3.1.2 Expression of AMIGO in primary cultured neurons and glia cells 
Other than neurons, we have also noted AMIGO staining in glial fibrillary 
acidic protein (GFAP)-positive astroglia, in both mouse brain and spinal cord 
sections (Fig 3-4 A and C). The antibody labeling is significantly blocked by the 
antigen AMIGO-GST recombinant protein (Fig 3-4 B and D) and is therefore very 
likely specific. AMIGO staining is also observed in 2', 3'-cyclic nucleotide 3'-
phosphodiesterase (CNPase)-positive oligodendroglia, particularly those in spinal 
cord sections (Fig 3-4 E). In order to verify the staining of AMIGO in both neurons 
and glia observed in brain sections, primary mouse astrocytes and rat 
oligodendrocytes were isolated and cultured. Primary cultures from mice/rat 
selectively enriched in either neurons or glia cells were then stained with AMIGO 
antibody (Fig 3-5 B and C). Western blotting using lysates from primary neurons or 
glia cell cultures also provided further support that AMIGO is expressed by all three 
types of neuronal cells (Fig 3-5 A). It is clear that immunofluorescence staining with 
our antibody, which is raised against an intra- rather than extracellular domain (as 
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previously reported), has revealed a more widespread AMIGO expression pattern 
than previously known. 
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Figure 3-2 Expression of AMIGO in adult mouse neurons 
30 μm cryosections of adult mouse brain were double-labeled with rabbit antibody against 
AMIGO (FITC, green) and mouse monoclonal antibodies against neuronal (dendritic) 
marker MAP-2 (Texas Red, red) or βIII tubulin (TuJ). The upper panel illustrates AMIGO 
co-staining with MAP2 in cerebral cortex (A), the hippocampus (B) and the cerebellum (C) 
in the dendrites. The Purkinje cell bodies and its dendritic tree projection into the molecular 
layer are clearly stained for AMIGO.  The lower panel illustrates AMIGO labeling with TuJ 
in the brain stem medulla oblongata (D) and spinal cord (E) section of adult mouse. Scale 





Figure 3-3 AMIGO expression pattern at the hippocampus  
The adult mouse brain section was double-labeled with AMIGO and mouse monoclonal 
antibody against neuronal (cell body) marker NeuN (Texas Red, red).  All the pictures were 
taken using the same image capture settings of the confocal microscope. A, dentate gyrus, 
DG; B, CA3; C, CA1; D, subiculum, Sb. Scale bar= 20 μm. The diagram below illustrates 
the domain structure of the hippocampus is adapted from 
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Figure 3-4 AMIGO expression in astrocytes and oligodendrocytes. 
The adult mouse brain (A) and spinal cord (C) sections were double-labeled with AMIGO 
and mouse monoclonal antibody against the astrocyte marker GFAP (Texas Red, red). 
Binding of the antibodies to tissue sections was blocked by AMIGO-GST recombinant 
protein in brain (B) and spinal cord sections (D), illustrating staining specificity. Scale bar = 
20 μm. AMIGO also co-labeled with CNPase-positive oligodendrocytes in the spinal cord 




Figure 3-5 AMIGO expression examined in primary cultures of neurons and 
glia 
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A: Western blotting shows that AMIGO is present in lysates of primary neuronal and glia 
cells, including rat astrocytes (50 μg), rat oligodendrocytes (25 μg), mouse cortical neurons 
(12.5 μg) and mouse astrocytes (50 μg). Mouse and rat total brain lysates (4 μg) were loaded 
as controls. B: Isolated mouse astrocytes double-labeled with AMIGO and astrocyte marker 
GFAP. Scale bar =10μm. C: Isolated rat oligodendrocytes double-labeled with AMIGO and 




We sought to examine if AMIGO level changes with the progression of 
morphological differentiation by mouse cortical neurons in the culture. As shown in 
Fig 3-6, the level of AMIGO increases with the number of days in vitro (DIV). 
AMIGO expression is low in the first few days of culture. As the neurons 
differentiate, extending first axons and then dendrites, AMIGO’s expression level 
increases, and peaked around DIV 7-12 before decreasing again. This time of 
AMIGO level elevation appears to coincide with the time of dendrite development 





Figure 3-6  AMIGO expression in cultured primary cortical neurons in vitro 
Cortical neurons cultured for different period in vitro (DIV 1 to 16) were harvested. 20 μg 
of cell lysate were subjected to SDS-PAGE and Western blotted with rabbit AMIGO 
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3.2 Polarized neuronal surface localization of AMIGO 
The prominent dendritic staining of AMIGO as noted above is interesting, 
and suggests that the molecule may have a specific function in dendrites. 
Verification of this dendritic localization of AMIGO had benefited from mutant 
constructs that we have generated. The distinct domains at the extracellular portion 
of the AMIGO molecule had prompted us to dissect their function by making 
domain-deletion mutants (Fig 3-7 A). Interestingly, when full-length AMIGO 
(AMIGO-FL, 493 amino acids) and its mutants, AMIGO-LRR, and AMIGO-Ig 
myc-tagged at the C-termini were transiently expressed in Neuro2A cells (Fig 3-7 B 
and C), we noted some differences in terms of their cell surface localization pattern 
and dynamics. Exogenously expressed AMIGO-Ig quickly assumes a cell surface 
staining pattern, while AMIGO-FL and AMIGO-LRR do not. AMIGO-FL appeared 
to be localized more internally, with only a small fraction appearing on the cell 
surface after 24 hr of transfection. AMIGO-LRR is not well localized to the cell 
surface at all; rather it exhibits an intracellular staining that is difficult to be 
associated with known membrane structures (Fig 3-7 C).  
When these constructs were transfected into 5 DIV primary cortical neurons 
and the respective expressions examined 24 hr later, AMIGO-Ig-labeled neurites 
appeared significantly longer than those labeled by AMIGO-FL, with AMIGO-LRR 
labeled neurite being the shortest (Fig 3-8 A). This difference in neurite lengths 
labeled by the over-expressed transgenes is confirmed by semi-quantitative counting 
(Fig 3-8 B). Furthermore, the longest neurite labeled by AMIGO-Ig are largely 
MAP-2 negative. 
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Figure 3-7 Differential expression patterns of AMIGO and its truncation 
mutants in Neuro2A cells. 
A: AMIGO and its mutants were cloned into pCIneo-myc2 vector with a myc-tag is at the C-
terminus. AMIGO-LRR composes the signaling sequence, full AMIGO-LRR domain, the 
transmembrane domain and the cytosolic tail. AMIGO-Ig composes the signaling sequence, 
Ig domain, the transmembrane domain and the cytosolic tail. (B) Neuro2A cells transfected 
with pCIneo-myc2 (VC), AMIGO-FL (FL), AMIGO-LRR (LRR) and AMIGO-Ig (Ig) were 
lysed and 10 μg of each lysate was subjected to SDS-PAGE and blotted with AMIGO 
antibody. C: Neuro2A cells transfected with AMIGO-FL (FL), AMIGO-LRR (LRR) and 
AMIGO-Ig (Ig) for 24 hr are fixed and subjected to immunocytochemistry. Anti-TuJ and 
Hoechst were used to counterstain the cells. Scale bar = 10 μm. 
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Figure 3-8 AMIGO and its truncation mutants label neurite with different 
lengths when expressed in primary cortical neurons 
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A: Cortical neurons (DIV 5) were transfected with the three AMIGO constructs (as in Fig 3-
7A) and double-labeled with AMIGO and MAP2 antibodies. Scale Bar = 20 μm. B: The 
neurite length of transfected cortical neurons was quantified based on AMIGO staining. 
Briefly, The extents of neurite outgrowth in each populations are visually quantified, and 
expressed as the proportion of cells ±SD, with their longest neurite with AMIGO-positive 
neurite being longer than 10 cell body lengths, <10 but >5 cell body lengths,<5 cell body 
lengths, out of total number of cells counted (AMIGO-FL: 161, AMIGO-LRR: 151, 
AMIGO-Ig: 140, The neurite length of untransfected cells were assessed based on TuJ 




We sought to further determine the reason underlying the difference in 
neurite length labeled by AMIGO-Ig compared to AMIGO-FL and AMIGO-LRR. 
As the time of exogenous expression may be too short (24 hr) to result in a 
difference in neurite length due to growth retardation or enhancement by the 
transfected products, we examined if AMIGO and its mutants had in fact been 
localized to different types of neurites. In order to avoid non-specific localization 
resulting from over-expression of the transgenes, we sought to limit the period of 
transgene expression. Primary cortical neurons were therefore transfected for a short 
period of 10 hr and then fixed for immunofluorescence labeling.  A double-labeling 
with the dendritic marker MAP2 indeed showed that AMIGO-FL and AMIGO-
LRR-labeled neurites are also MAP2-positive, and these are both therefore 
predominantly dendritic. However, AMIGO-Ig labeled neurites (as also shown in 
Fig 3-8) are largely MAP-2 negative (Fig 3-9), but were positive for the axonal 
markers tau and TuJ (data not shown). Therefore, in morphologically mature 
primary neurons, endogenous AMIGO and transfected AMIGO-FL and AMIGO-
LRR are largely dendritic, while AMIGO-Ig is predominantly axonal. These results 
are novel as specific dendritic distribution of AMIGO was not previous known. 
They are however very much in line with our observations in brain cryosections (Fig 
3-2). 
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Figure 3-9 AMIGO-FL and AMIGO-LRR are localized to MAP-2-positive 
dendrite, but not AMIGO-Ig  
DIV 4 cortical neurons were transfected with AMIGO constructs for 10 hr and double 
stained with rabbit myc and mouse MAP2 antibodies. Scale bar= 20μm. 
 
 
3.3 The role of AMIGO in dendritic outgrowth 
In view of the predominant dendritic localization of AMIGO, we next asked 
if AMIGO has a specific role in dendritic outgrowth. We first attempted to express 
AMIGO-FL and its mutants in primary cortical neurons to assess their effects on 
dendritic length. This approach met with two difficulties, Firstly, transfected 
neurons become rather unhealthy after 36 hr, which limits prolonged transfection 
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periods. Furthermore, particularly in neurites expressing AMIGO-LRR, MAP2 
staining clearly diminished after prolonged transfection periods. This made 
estimation of dendritic length difficult. We therefore sought to assess the role of 
AMIGO on dendrite growth using a loss-of-function approach. The expression of 
endogenous AMIGO in cortical neurons 4 DIV is silenced by transfection with two 
different 27-mer dicer-ready AMIGO siRNA, which effectively reduced AMIGO 
protein levels, in both cases, by >60% at 54 hr after transfection (Fig 3-10 B). 
Compared to neurons transfected with a scrambled control siRNA, those transfected 
with AMIGO siRNA had significantly shorter MAP2-positive dendrites (Fig 3-10A 
and C). Our results therefore showed that endogenous AMIGO is important for 
dendritic outgrowth and development, at least in vitro. 
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Figure 3-10 siRNA silencing of AMIGO attenuates dendrite outgrowth of 
primary cortical neurons. 
A: Dendritic outgrowth of primary cortical neurons (4 DIV) transfected with scrambled (SC) 
or two different AMIGO siRNAs (siRNA-1 and siRNA-3) were assessed by MAP2. Cells 
were incubated for 24 h with the siRNA, the transfection and incubated in normal media for 
another 30 h before fixation and immunofluorescence labeling. Scale bar= 20 μm. B: 
Western blot using the cell lysates (20 μg) from cortical neurons mentioned in (A) and 
blotted with AMIGO or γ-tubulin antibody. C: Graph comparing the extent of dendrite 
growth in mouse primary cortical neurons transfected with scrambled or AMIGO siRNA 
The extents of dendrite outgrowth in each populations are visually quantified, and expressed 
as the proportion of cells ±SD, with their longest MAP-2 positive neurite being longer than 
5 cell body lengths, <5 but >3 cell body lengths, or <3 cell body lengths, out of total number 
of cells counted (Scramble: 106, siRNA-1: 93, siRNA-3: 83). 
 
 









4 RESULTS: NGR2 EXPRESSION IN THE BRAIN AND 
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4.1 Expression analysis of NgR2 
4.1.1 NgR2 expression in mammalian cells 
We have previously generated NgR1 specific antibodies (Liao et al., 2004). To 
examine NgR2 expression and functions, NgR2 specific antibody was raised against its 
C-terminal unique domain (amino acids 311-420, see Fig 1-4) in rabbits. The rabbit 
antibody specifically recognizes NgR2 by immunoblotting and immunocytochemistry. 
In transfected neuroblastoma cell line Neuro2A, the myc-epitope-tagged NgR1, NgR2 
and untagged NgR3 are expressed in > 20% of the cells (data not shown). Affinity-
purified rabbit anti-NgR2 antibody detected, by Western blot analysis, a doublet band of 
65 kDa and 75 kDa. As the predicted size of NgR2 is 42 kDa, the doublet band are more 
likely to represent a highly glycosylated form of this surface protein (Fig 4-1 A). Anti-
myc epitope antibody also labeled the same two bands, and the existence of these two 
forms of NgR2 had been shown previously by others (Venkatesh et al., 2005). The NgR2 
antibody recognizes neither NgR1 nor NgR3 (Fig 4-1 A). In immunofluorescence 
analysis, NgR2 antibody also showed specific surface staining that coincided with myc 
staining in the myc-NgR2 stable cell line, but showed no staining in myc-NgR1 stable 
cell line (Fig 4-1 B).  The staining specificity of the NgR2 antibodies is indicated by 
efficient blocking with the antigen NgR2-GST recombinant protein (Fig 4-1 C).  
NgR1 was previously shown as a GPI-linked protein and localized to the lipid 
raft (Fournier et al., 2001, Pignot 2003, Liao et al., 2004). As NgR1 homologues contain 
putative glycosylphosphatidyl inositol (GPI) signal sequences, we sought to determine if 
NgR1 and NgR2 transfected into Neuro2A is indeed expressed as a GPI-anchored 
protein and targeted to the plasma membrane. After phosphatidylinositol-phospholipase 
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C (PI-PLC) treatment, the surface staining of both NgR1 and NgR2 was lost (Fig 4-1 D), 
indicating that a good majority of NgR2 and NgR1 are properly expressed and localized 
in their GPI-linked form at the cell surface.  
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Figure 4-1  NgR2 antibody specificity and NgR2 subcellular localization in 
Neuro2A cells   
Cell lysates of Neuro2A cells (15 µg per lane) were subjected to SDS-PAGE and western blotted 
with NgR2 antibody raised in rabbits A: The arrow heads indicate the size of myc-NgR2. The 
rabbit antibody recognizes a doublet band of myc-NgR2 (arrow and arrow head). VC: pCIneo-
myc vector control lysate; NgR1, myc-NgR1 lysate; NgR2, myc-NgR2 lysate; NgR3, NgR3 
lysate. B: NgR2 antibody shows specificity and reveals surface localization of NgR2 and NgR1 
proteins. The NgR2 antibody is able to recognize the myc-NgR2 of NgR2 Neuro2A stable cell 
lines but not myc-NgR1 of NgR1 Neur2A stable cell line. Mouse myc (9E10) antibody can 
recognize both myc-NgR1 and myc-NgR2 expressing cells. C: Rabbit NgR2 antibody or NgR2 
antibody binding with the NgR2-GST recombinant protein prior to staining were used to label 
the adult mouse brain sections. The anti-NeuN (marker of neuron cell body) antibody was used 
to show the cerebral neurons. Scale bar = 20 μm..  D: Phosphatidylinositol-phospholipase C (PI-
PLC) treatment (1U/ ml at 37ºC for 2 hours) cleaves a majority of NgR1 and NgR2 and the 




4.1.2 Comparative analysis of NgR1 and NgR2 in mouse central nervous 
system 
We used our specific antibodies to analyze and compare the expression of NgR1 
and NgR2 in adult mouse CNS. NgR1 is abundant in particular neuron types, such as 
cerebellar Purkinje cells. Distinct staining of NgR1 is found in the large cell bodies as 
well as the elaborate dendritic tree of Purkinje neurons. Fig 4-2 shows clear 
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colocalization of NgR1 and MAP2 stainings in the Purkinje cell dendritic tree (Fig 4-2 
A). However, NgR1 appears to be absent from β-III tubulin (TuJ) positive axons in 
spinal cord white manner (Fig 4-2 B). NgR1 is also not present in GFAP positive 
astrocytes (Fig 4-2 C) but is moderately expressed in some CNPase-positive 
oligodendrocytes (Fig 4-2 D) in the spinal cord.  
Previous study shows that NgR2 mRNA was highly expressed in brain cortex, 
hippocampus (Pignot et al., 2003; Lauren et al., 2003) and retina (Venkatesh et al., 2005). 
We have therefore examined the protein level of NgR2 in the adult mouse brain and 
spinal cord. NgR2 is widely distributed in adult mouse CNS neurons. We detected the 
presence of NgR2 staining in the olfactory neurons, all layers of cerebral cortical 
neurons, thalamus neurons (data not shown), hippocampus as well as cerebellar Purkinje 
neurons (Fig 4-3). NgR2 shows neuronal cell body staining but was not clearly seen in 
MAP2-positive dendrites (Fig 4-3 B, C, D). Contrasting to NgR1 staining, NgR2 
antibodies clearly stained the neurons and the axon tract in the spinal cord. NgR2 
staining colocalizes with TuJ but not MAP2 in the spinal cord (Fig 4-4 A and B). NgR2 
can also be found at modest levels in some CNPase-positive oligodendrocytes in the 
spinal cord, but not in astrocytes (Fig 4-4 C and D). In the hippocampus, NgR2 
prominently stains CA3 neurons and those at the subiculum region (Fig 4-5). 
Our NgR1 and NgR2 specific antibodies have therefore revealed some 
interesting and novel properties of both proteins. Firstly, the lack of axonal localization 
of NgR1 at the spinal cord axons may indicate that it is not a key player in axonal 
growth inhibition in spinal cord injuries. Secondly, the axonal localization of NgR2 in 
neurons of many brain areas suggests that it may have a pathophysiological role in 
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limiting adult axonal regeneration after CNS injury. Finally, expressions of both NgR1 
and NgR2 in oligodendrocytes are rather novel and surprising, and have not been 
















Figure 4-2 NgR1 expression in adult mouse CNS.   
Immunohistochemistry study reveals NgR1 (FITC, green) is highly expressed and colocalized 
with MAP2 (Texas red, red) in Purkinje cells in the cerebellum (Panel A). However, NgR1 
appears to be absent in TuJ positive axons in the spinal cord (Panel B), or GFAP positive 
astrocytes (Panel C). NgR1 staining could also be seen in CNPase positive oligodendrocytes in 
the spinal cord (Panel D) scale bar = 20 μm. (see next page). 
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Figure 4-3 Expression of NgR2 in adult mouse neurons.   
NgR2 (FITC, green) is present and colocalized with neuronal markers TuJ (A, olfactory bulb; D, 
cerebellum) and MAP2 (B, cerebral cortex; C, hippocampus) (Red, Texas red) in different parts 
of the mouse brain. Scale bar = 20 μm.  
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Figure 4-4 NgR2 is present in axon tracts and not enriched in glia cells.  
NgR2 (FITC, green) colocalized with TuJ (Texas red, Red) in the spinal cord (A) but not 
colocalized with MAP2 in the spinal cord white matter (B, big arrow). NgR2 is also present in 
the neuron cell body in spinal cord (B). NgR2 does not colocalize with GFAP in the astrocytes 
(C) and it could be weakly expressed by some CNPase positive oligodendrocytes (D, arrow). 
Scale bar =20 μm. 
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Figure 4-5 The NgR2 expression in the hippocampus 
The adult mouse brain section was double-labeled with NgR2 and mouse monoclonal antibody 
NeuN. All the pictures were taken using the same image capture settings of the confocal 
microscope. A, dentate gyrus, DG; B, CA3; C, CA1; D, subiculum, Sb. Scale bar= 20 μm. 
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4.2 Expression and localization of NgR family members and LINGO-1 
in primary cortical neurons 
To examine and compare the neuronal subcellular localization of NgR2 and its 
related proteins, we transfected myc-NgR1, myc-NgR2, NgR3 and LINGO-1 expression 
constructs into mouse cortical neurons. Co-transfection with EGFP was used to visualize 
the transfected neurons.  Neurons were fixed after 24 hr to limit the overexpression of 
the transgenes. As shown in Fig 4-6, EGFP filled the entire neuronal cell body and its 
associated neurites. NgR1 and NgR3 can be found in both cell bodies and neurites. 
However, the expression of NgR2 and LINGO-1 are more clearly confined to the cell 
body in most of the transfected cells (Fig 4-6). The NgR2 and LINGO-1 transfected 
cortical neurons have similar neurite length compared with neurons transfected with 
EGFP only. Therefore, the accumulation of these proteins in the cell body did not appear 
to affect the neurite growth, at least not within the time frame use in the experiment. 
 




Figure 4-6 The expression and subcellular localization of NgR homologues and 
LINGO-1 in primary cortical neurons. 
EGFP were co-transfected with myc-NgR1, myc-NgR2, NgR3 and LINGO-1 into the mouse 
cortical neurons. Cells were fixed and stained with rabbit polyclonal anti-myc antibody (NgR1, 
NgR2), anti-NgR3 (NgR3) and LINGO-1 (LINGO-1) rabbit polyclonal antibodies (Texas red, 
Red). Scale bar = 20μm. 
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4.3 NgR2 interacting with NgR1 co-receptors   LINGO-1 and p75NTR 
in Neuro2A cells 
When the homologues of NgR1, NgR2 and NgR3, were firstly identified, they 
were shown not to bind to the classical MAIs such as Nogo or MAG (Barton et al., 
2003). It was subsequently reported that NgR2 interacts with MAG, one of the known 
NgR1 ligand. However, it was not known if the NgR1 co-receptors LINGO-1 or p75NTR 
could be likewise engaged by NgR2. To determine whether LINGO-1 and NgR2 can 
physically interact, Neuro2A cell lines are used in co-immunoprecipitation (Co-IP) 
studies. We first established myc-NgR2 stably expressing cells using Neuro2A, and then 
transfected these with a LINGO-1 expression construct. To perform Co-IP, we used a 
mouse monoclonal antibody against the myc epitope (9E10) and a rabbit polyclonal 
antibody against the LINGO-1 intracellular domain to avoid potential antibody masking 
and Ig heavy chain background. Myc-NgR2 is expressed in almost 100% of population 
of the Nuero2A stable cell lines (Fig 4-1 B). LINGO-1 transgene expression is 
moderately (around 10%) after transient transfection. Normal rabbit and mouse IgGs 
were used as IP controls. Myc-NgR2 was only detected in anti-LINGO-1 but not rabbit 
IgG control immunoprecipitate (Fig 4-7 A). Conversely, LINGO-1 was detected in anti-
myc but not mouse IgG control immunoprecipitate (Fig 4-7 B).  
We also checked if NgR2 could interact with p75NTR, another known NgR1 co-
receptor. Neuro2A cell line has abundant endogenous p75NTR , which is detectable by 
western blot. Anti-myc 9E10 was able to immunoprecipitate the endogenous p75NTR (Fig 
4-7 C). However, the p75NTR antibody (which we have gotten from a commercial source) 
failed to Co-IP myc-NgR2 specifically, which is probably due to its inability to perform 
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IP (The antibody could not even IP its cognate antigen, p75NTR, not shown). These 
results suggest that, like NgR1, NgR2 could also interact with LINGO-1 and p75NTR. 
Due to the lack of appropriate antibodies, we were unable to examine if NgR2 also binds 
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Figure 4-7 NgR2 interacts with LINGO-1 and p75NTR.  
A: 500 μg of cell lysates were immunoprecipitated by LINGO-1 rabbit antibody (lane 2) or total 
rabbit IgG antibody (lane 3).  The elutions were then western blotted (WB) with anti-myc 9E10 
mouse monoclonal antibody. B: The reciprocal IP were carried out using 9E10 anti-myc 
antibody (lane 2) or total mouse IgG antibody (lane 3). The elutions were then western blotted 
with LINGO-1 rabbit antibody. 25 µg of total cell lysate was loaded as input (A, lane 1 and B, 
lane 1). C: 1mg of cell lysates were immunoprecipitated by anti-myc 9E10 antibody (lane 2) or 
total mouse IgG antibody. The elutions were then western blotted with p75 rabbit antibody. 15 
ug of total cell lysate was loaded as input (C, lane 1). Arrows point towards the expected 
position of the respective proteins in question. 
 
Does NgR2’s interaction with LINGO-1, demonstrated above in vitro, have any 
physiological meanings? Before performing any functional studies, the mRNA 
expression profiles of NgR1, NgR2, LINGO-1, p75NTR and TROY in Neuro2A were 
examined. In untreated, control cells, basal levels of NgR1, NgR2 (data not shown) and 
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moderate LINGO-1 expression were found in Neuro2A cell lines. p75NTR is highly 
expressed. However, TROY is absent in Neuro2A cells (Fig 4-8 A). Retinoic acid (RA) 
induced differentiation lowers the transcript levels of LINGO-1 in myc-NgR1 and myc-
NgR2 expressing stable Neuro2A cells, but not in the untransfected Neuro2A cells (Fig 
4-8 B). The levels of p75NTR are also not effected by RA induction. These observations 
suggest that neuronal differentiation, in conjunction with NgR1 or NgR2 over expression, 
can affect the LINGO-1 expression via an unknown mechanism.  
To gain insight into possible neurite growth inhibitory activity and mechanism of 
NgR2, we induced the NgR1 and NgR2 stably expressing Neuro2A cells. We then 
evaluate possible morphological changes associated with neurite outgrowth inhibition. 
MAG, expressed as an immunoglobulin constant region (Fc) fusion protein (MAG-Fc) 
was produced in HEK 293 cells and used as the MAI ligand (see section 2.4.3). Myc-
NgR1 and myc-NgR2 expressing stable Neuro2A cells were grown on coverslips with or 
without MAG-Fc coated onto their surfaces. Cells were then transfected with constructs 
encoding either LINGO-1 or a dominant negative mutant of LINGO-1 (LINGO-1-DN), 
and subsequently induced to differentiate by retinoic acid (RA). The Neuro2A cells 
stably expressing NgR1 and NgR2 cells showed much shorter or no processes when they 
co-expressed LINGO-1. As shown in Fig 4-9, when grown on MAG-Fc substrate, these 
cells rounded up and appeared to loss adherence. No such effect was observed in 
LINGO-1-DN transfected cells. Co-expression of NgR2 and LINGO-1 could therefore 
render Neuro2A cell susceptible to the neurite growth inhibitory effects of MAG. 
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Figure 4-8 RNA expression profile for NgRs and related proteins in Neuro2A cells. 
Neuro2A cell lines stably expressing NgR1 or NgR2 and normal, untransfected Neuro2A cells 
are cultured in 10% FBS DMEM (uninduced) or 0.5% FBS with 10 μM retinoic acid for 3 days 
before harvest. 0.5 μg of total RNA from cells and 0.1 μg from mouse brain were used as 
templates for RT-PCR (35 (A) or 25 (B) cycles using the respective primers) (Table 2.2) A: The 
mRNA expression profile LINGO-1, p75NTR and TROY for uninduced Neuro2A (N2A), NgR1 
stable, NgR2 stable and  mouse brain (mouse)  total RNA. B: The mRNA expression of LINGO-
1 and p75NTR in RA-induced wild type Neuro2A cells (N2A i), NgR1 (NgR1 i), NgR2 (NgR2 i) 


















Figure 4-9 The effect of MAG-Fc on neurite induction and cell morphology of 
Neuro2A cells stably expressing NgR1 and NgR2 transfected with LINGO-1 or 
LINGO-1-DN.  
Neurite growth in N2A cells, with either LINGO or LINGO-DN after induction with MAG-Fc 
stimulation. Cell were double-labeled with anti-LINGO-1 (LINGO, FITC, green) and 9E10 
(myc-NgR1, myc-NgR2, Texas red, Red) and counterstained with Hoechst. Scale bar=20μm. 
(See next page). 
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5.1 AMIGO expression and possible functions in the adult CNS 
5.1.1 AMIGO is expressed in multiple brain cell types 
In this study, we have examined the expression of AMIGO in the CNS using 
specific antibodies raised against the intracellular domain of AMIGO. Our western blot 
revealed a molecular size of AMIGO that is around 20 kDa longer than the calculated 
size based on its cDNA open reading frame. This suggests that AMIGO might be 
glycosylated. Indeed, the AMIGO band of mouse/rat brain and cortical neuron extracts 
were a little smeary, which could indicate the presence of a heterogenous population 
with different extent of glycosylation. 
Our studies demonstrate that AMIGO is present in multiple cell types in the 
adult rodent brain. AMIGO is not only expressed in neurons, but is also present in glia 
cells, such as astrocytes and oligodendrocytes. At a higher resolution, we found 
AMIGO enriched in the dendrites instead of axons in neurons. 
The expression pattern of AMIGO has been previously reported (Kuja-Panula et 
al., 2003) in rat brain. We found that AMIGO expression profile in mouse during 
development is, on the whole, similar to what was observed in rats. However, unlike 
previously reported for rat, there is no dramatic down-regulation of AMIGO observed 
in newborn mouse (Fig 3-1 B). Contrasting to AMIGO localization in the axonal fiber 
depicted in the previous report, we showed evidence that AMIGO expression was in 
fact stronger in dendrites in cortical neurons, hippocampal neurons and Purkinje cells in 
the cerebellum (Fig 3-2 A, B and C), and hardly detectable in the axons prominently 
stained by TuJ in brain stem and spinal cord (Fig 3.2 D and E).  We confirmed that 
AMIGO is highly expressed in the hippocampus in the adult brain. Previous work had 
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shown that the most intense signal is found at the dentate gyrus. We found that AMIGO 
expression increase in a gradient from dentate gyrus, to CA3, CA1, and the subiculum.  
AMIGO expression in the glial cells was not previously shown. We noticed that 
our AMIGO antibody stained astrocyte-like cells, and confirmed this by double labeling 
of AMIGO and GFAP in the mouse brain and spinal cord cryosections. The specificity 
of the staining was confirmed by antigen (AMIGO-GST) blocking (Fig 3-4 B and D). 
Further confirmation of the AMIGO’s presence in astrocytes comes from 
immunocytochemistry and western blotting with isolated astrocytes in culture (Fig 3-5 
A and B). There appear to be some differences in the AMIGO expression profile by 
different subtypes of the astrocytes in different brain regions. Further investigations will 
be needed to see if AMIGO expression is indeed astrocyte subtype specific. We also 
found some oligodendrocytes expressing AMIGO in spinal cord sections (Fig 3-4 E), 
and there is indeed specific AMIGO expression in isolated oligodendrocytes (Fig 3-5 A 
and C).  
The reason for the apparently more elaborate AMIGO expression compared to 
that previously observed by Kuja-Panula et al. (2003) is not particularly clear. The main 
difference between our reagents is that our antibodies were raised against the entire 
intracellular domain of AMIGO. On the other hand, the antibody used by Kuja-Panula 
et al. (2003) was raised against a peptide sequence at the extracellular region of 
AMIGO. A closer examination of the peptide sequence used by Kuja-Panula et al. 
(2003) indicates that it is very close to the transmembrane domain of AMIGO. It is 
plausible that the proximity of the epitope to the membrane may have weakened the 
general intensity of labeling of the authors’ antibodies. 
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5.1.2 Neuronal subcellular localization of AMIGO 
In attempts to delineate the functions of the distinct domains found at the 
extracellular portion of AMIGO, we have made the AMIGO-LRR and AMIGO-Ig 
mutant constructs, with one of the respective domains detected. Interestingly, we 
observed that the mutant AMIGO proteins exhibit very different subcellular 
localizations. AMIGO-Ig quickly assumed a cell surface localization when expressed in 
Neuro2A cells, but this is not so for AMIGO-FL or AMIGO-LRR. The latter two 
assumed largely intracellular staining patterns. In transfecting these constructs into 
primary cortical neurons, we had initially intended to ask if their over-expression would 
affect cortical neurite growth. We observed that AMIGO-Ig labeled long, thin neurites. 
On the other hand, AMIGO-LRR and AMIGO-FL are found on neurites which are 
shorter and have a thicker branch point from the cell body. This observation is 
surprising, and cannot be explained by the over-expression protein affecting neurite 
growth differently, as the time from transfection to harvest is merely 10 hr. A more 
likely explanation is that AMIGO-Ig was in fact localized to a different type of neurite 
compared to AMIGO-FL and AMIGO-LRR. Indeed, further investigations by double-
labeling with axonal and dendritic markers showed that AMIGO-Ig was primarily 
localized to the axons, while AMIGO-FL and AMIGO-LRR were primarily localized to 
the dendrites after transient transfection. In some AMIGO-FL overexpressing neurons, 
weak axonal labeling of AMIGO could also be seen in the AMIGO-FL transfected 
neurons. 
Neurons are polarized cells with two kinds of processes, the axons and the 
dendrites. Typically, cortical neurons have a long axon and multiple shorter dendrites, 
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with the specification of the axon preceding that of dendrites (Ye and Jan 2006). The 
formation of the axons and dendrites during morphological differentiation of primary 
neurons in culture has been well documented for hippocampal neurons (Dotti et al., 
1998). Polarized membrane traffic to these two different domains of the neuron is 
required for both establishment and maintenance of neuronal polarity (Arimura and 
Kaibuchi, 2005; Wiggin et al., 2005).  
In general, polarized targeting to different neuronal surface domains can be 
achieved in several ways. Although neurons lack an equivalent of tight junctions, 
cytoskeletal-membrane protein complexes constituting the initial segment fence found 
at the axon hillock (Winckler et al., 1999) could prevent free movement of membrane 
proteins to axonal domains. Selective, directed targeting of membrane cargoes in 
specific domain bound carriers has been observed for dendritic proteins (Setou et al., 
2000; Juttner and Rathjen, 2005). On the other hand, some membrane cargo-ferrying 
carriers are not specifically targeted, and could find their way into the associated 
cytoplasmic region of both axons and dendrites. This is particularly the case for those 
utilizing plus-end-directed microtubule motors, which is present in both axon and 
dendrite (Whelt, 2004). For these, selective membrane docking/fusion is presumably 
required for eventual domain specific incorporation of cargo (Burack et al., 2000). 
Polarized surface transport of membrane materials is required in the maintenance of 
adult neuron function, and is also acutely needed in polarized neurite growth during 
development and differentiation. 
Neuronal dendrites are elaborate, multi-branched structures. The domain 
specific membrane protein targeting mechanism is totally different from axons to 
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dendrites. We observed that AMIGO-FL and AMIGO-LRR is transported primarily to 
the dendrites. However, when the LRR domain is deleted, the resulting AMIGO-Ig is 
instead localized to the axons. This is an interesting phenomenon, although the 
underlying mechanism is yet unclear. As the LRR and Ig domains are both 
luminal/extracellular, they are unlikely to contain the classical vesicular targeting 
signals (which are usually recognized by cytoplasmic factors). Without the LRR domain, 
AMIGO-Ig may be actively targeted to axons, as indicated by its primary labeling of 
axons and not dendrites. This may occur by default, and perhaps aided by the fact that 
absence of LRR somehow alleviates an inhibition of axonal transport. The latter would 
also explain why AMIGO-FL and AMIGO-LRR are more dendritically rather than 
axonally targeted.  
 
5.1.3 The role/effect of AMIGO in neurite growth 
In view of AMIGO’s localization to dendrites, we had initially attempted to ask 
if the overexpression of AMIGO and its mutants have any effect on dendritic neurite 
extension. However, the overexpression of the AMIGO and its mutant proteins had 
made the assessment of dendritic growth difficult. MAP2 staining is significantly 
diminished in transfected neurons with a longer time of incubation after transfection 
We have therefore resorted to ask if silencing of endogenous AMIGO in primary 
cortical neurons could affect dendritic growth. We found that AMIGO silencing indeed 
attenuated dendrite outgrowth significantly. We also observed that AMIGO expression 
levels roughly coincided with the onset of dendrite extension in culture. Taken together, 
these evidences suggest AMIGO is important in dendritic development. The 
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downstream signaling mechanism for AMIGO’s effect on dendritic growth would be an 
interesting pursuit for the immediate future.  
 
5.1.4 Other possible roles of AMIGO in neurons 
As the AMIGO homologue AMIGO2/Alivin-1 promotes survival of neurons 
(Ono et al., 2003) and has an anti-apoptotic or survival promoting role in epithelial cells 
(Rabenau et al., 2004), we have also checked if AMIGO has any neuroprotective effect 
on Neuro2A cells. Our preliminary data indicate that over expression of AMIGO in 
Neuro2A cells did not provide significant protection against classical apoptosis insults 
such as staurosporine and serum withdrawal (data not shown). As we have not done a 
comparative analysis with AMIGO-2 in this regard, it is at the moment unclear if 
AMIGO has no survival signaling capacity or that we have not used the right system in 
our investigations. 
5.2 NgR2 expression in the adult CNS and its possible role in 
neuronal regeneration 
5.2.1 The MAI- NgR1 axis in inhibition of neuronal regeneration 
The myelin-associated inhibitors have all been shown to bind to and exert their 
neurite outgrowth inhibitory effect through the Nogo-66 receptor (NgR1). Other than 
Nogo-66, another prominent ligand for NgR1 is the myelin-associated glycoprotein 
(MAG). MAG is one of the first proteins to be expressed during myelination, and it is 
localized to the myelin sheath in contact with the axon. It is a cell adhesion molecule 
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that mediates sialic-acid dependent cell-cell interactions between neuronal and 
myelinating cells. MAG has been shown to enhance neurite outgrowth from DRG 
neurons from 1-day-old rats, but it has a pronounced inhibitory effect on outgrowth 
either from adult DRG neurons or from developing cerebellar neurons. MAG exists 
both in the CNS and PNS myelin (Tomita et al., 2007, Shen et al., 1998).  It not only 
affects axonal elongation and regeneration, but also on axonal branching.  
As NgR1 does not span the membrane, its signaling is critically dependent on 
membrane spanning co-receptors. Three such co-receptors have been identified for 
NgR1, namely p75NTR, TROY/TAJ and LINGO-1. p75NTR has been known as the low 
affinity neurotrophin receptor, and has surprisingly diverse roles in the nervous system. 
These include the neurotrophic effect of promoting cell differentiation and survival, 
inhibition of axon regeneration and elongation, to the initiation of apoptotic cell death. 
This diversity can be explained by the complex formation of p75NTR with other 
receptors and multiple signaling molecules that interact with the intracellular domain of 
p75NTR (reviewed by Bandtlow and Dechant 2004, Yamashita et al 2005). There are 
many examples of elevated p75NTR expression in the adult brain and spinal cord after 
injury, inflammation and stress. Interestingly, many neurons including hippocampal and 
cortical neurons, oligodendrocytes and microglial cells ordinarily show low levels of 
p75NTR. However, after ischaemia, seizure, axotomy or other forms of stress, the 
expression of this receptor is considerably elevated in these types of cells (Chao 2003).  
Another NgR1 co-receptor is LINGO-1. Other than a co-receptor of NgR1, 
LINGO-1 also has other physiological and pathological implications in CNS, for 
example in regulating oligodendrocyte differentiation and myelination (Mi et al., 2005). 
Chapter 5:                                                                                                          Discussion 
 90
Recent studies have also shown that LINGO-1’s expression is elevated in the substantia 
nigra of Parkinson’s disease (PD) and damaged dopaminergic (DA) neurons of mice 
(Inoue et al., 2007). The blocking of LINGO-1 signaling by soluble LINGO-1-Fc, DN-
LINGO-1 or LINGO-1 antibody shows neuroprotection and enhanced neurite growth 
effect on midbrain DA neurons in vitro. The C-terminal EGFR like tyrosine 
phosphorylation site of LINGO-1 binds to EGFR and negatively regulates EGFR/Akt 
signaling pathway and neuronal survival in certain type of neurons (Inoue et al., 2007).  
Much research on MAI-NgR1 had focused on the therapeutic and clinical 
application in improving recovery after CNS injury. Many studies have demonstrated 
substantial benefits in interfering with the MAI-NgR1 interaction/function on axonal 
regeneration and functional recovery. Mouse monoclonal IN-1 antibody against Nogo-
A improve axonal regeneration and the recovery after spinal cord injury (Schnell and 
Schwab, 1990; Bregman et al., 1995). The Nogo-66 antagonist peptide (NEP1-40) 
blocks Nogo-66 or CNS myelin inhibition of axonal outgrowth in vitro (GrandPre et al., 
2002). Soluble NgR1 blocks the ligand binding to the surface bound NgR1 promotes 
axonal sprouting and recovery after spinal injury (Li et al., 2004). Chromophore-
assisted laser inactivation of MAG permitted significant optic nerve regeneration 
(Wong et al., 2003). Antagonists of LINGO-1 also promote functional recovery and 
axonal sprouting after spinal cord injury (Ji et al., 2006). Similar benefits have also been 
noted for stroke recovery (Papadopoulos et al., 2002; Lee et al., 2004; Seymour et al., 
2005).  
Genetic analysis has yielded somewhat unclear and conflicting results pertaining 
to the in vivo roles of both Nogo and NgR1 in terms of inhibition of neuronal 
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regeneration (Kim et al., 2003, Simonen et al 2003, Dimou et al 2006, Zheng et al., 
2003, Kim et al., 2004, Zheng et al., 2005, Woolf, 2003). Both Nogo and NgR1-
deficient mice, depending on the genetic background and the exact genetic nature of 
targeted deletion induced, exhibited only none to modest improvement in CNS neuronal 
regeneration. The reason for the lack of a drastic improvement in neuronal regenerative 
capacity in the knockout mice is not yet clear. One possible reason is that other 
inhibitors had compensated for the absence of Nogo or NgR1. These other myelin-
associated inhibitors include the large family of molecules collectively known as the 
chondroitin sulfate proteoglycans (CSPG) (Galtrey and Fawcett, 2007). After injury, 
CSPG expression is rapidly upregulated by reactive astrocytes, forming an inhibitory 
gradient that is highest at the centre of the lesion and diminishes gradually into the 
penumbra (McKeon et al., 1991, Morgenstern et al., 2002, Yiu and He, 2006). 
The identification of the NgR1 homologues NgR2 and NgR3 have also 
prompted suspicions that these might mediate neuronal growth inhibition in the absence 
of NgR1. In view of this, we have undertaken investigations on the expression pattern 
of NgR2 in the adult CNS, as well as its possible mechanism in neurite growth 
inhibition. 
5.2.2 NgR2 expression pattern in the adult mouse brain in comparison with 
NgR1 
We have generated NgR1 and NgR2 specific antibodies in rabbits, taking 
advantage of the fact that the C-terminal domains of NgR1 and NgR2 are non-
homologous and are soluble when expressed as GST-fusion proteins in E.coli. With 
these specific antibodies, we then performed comparative immunohistochemical 
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analysis of the distribution patterns of these homologues in adult mouse brain. Our PI-
PLC experiment showed that like NgR1, NgR2 is also localized at the cell surface as a 
GPI-anchored protein (Fig 4-1 D). Interestingly, our immunohistochemical analysis 
showed that NgR2 is widely distributed and is expressed in most kinds of neurons (Fig 
4-3). It strongly stains axon tracts in the spinal cord (Fig 4-4). On the other hand, NgR1 
expression in the brain and spinal cord is apparently more limited. We found it to be 
highly expressed only in the cell bodies and dendritic tree of Purkinje neurons (Fig 4-2). 
These observations suggest that NgR2, should it also exhibit equivalent ability in 
transducing neurite growth inhibition signals as NgR1, could in fact be a more relevant 
factor in inhibiting  neuronal regeneration in multiple locations of the adult CNS.  
To our surprise, we have also observed that both NgR1 and NgR2 are expressed 
in oligodendrocytes (Fig 4-2 D and Fig 4-4 D). A recent report from another lab has 
also documented NgR1 expression in oligodendrocytes (Guo et al., 2007). After spinal 
cord injury, the authors detected changes in the levels of NgR1 and its ligand OMgp in 
both neurons and oligodendrocytes. The expression of both proteins increased 
immediately after injury and then decreased gradually. The exact role of NgRs in the 
CNS, other than restriction of axonal plasticity in adult neuronal networks (Yiu and He, 
2006) remains unknown, but emerging evidence suggests that NgR1 expression may not 
be restricted to neurons. Recently, NgRs has also been implicated in inflammation of 
peripheral nerve (Fry et al., 2007). Both NgR1 and NgR2 are found on the cell surface 
of macrophages in crushed rat sciatic nerves. Contrasting to spinal cord injury, in which 
NgR1 expression is up-regulated, the expression level of NgR1 and NgR2 diminished in 
the crushed sciatic nerves but increased in the macrophages. NgR1 and NgR2 on these 
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cells interact with MAG, which repelled the macrophages from the newly synthesized 
myelin.  
 
5.2.3 NgR2’s role and mechanism in neurite growth inhibition  
We attempted to examine the effect of NgR2 and its co-receptors on neurite 
growth in mouse primary cortical neurons. When myc-NgR1 and myc-NgR2 constructs 
were transfected into DIV 5 cortical neurons for 24 h, we noted that the neurites labeled 
by myc-NgR2 or LINGO-1 were significantly shorter than neurites labeled by myc-
NgR1. This could mean that NgR2 and LINGO-1 transgene expression had reduced 
neurite length significantly compared to NgR1. However, considering that this effect 
was observed within a short time of 24 h, we suspected that NgR1, NgR2 and LINGO-1 
may not be equally distributed or localized along the membranes of the neuronal 
processes.  
To confirm this, NgR1 homologues and LINGO-1 were co-transfected together 
with an EGFP expression construct, whose product is evenly distributed in the neuronal 
processes and provides a more independent marker for neurites. Myc-NgR2 and 
LINGO-1 were indeed found to be more confined the cell body of the neurons, whereas 
myc-NgR1 and NgR3 are more evenly distributed and colocalized with EGFP in the 
processes (Fig 4-6). However, we could not exclude the possibility that over expression 
of EGFP could affect the localization of NgR1 homologues and LINGO-1. In any case, 
the differential distribution of transgenes on neuritic processes made it difficult for us to 
examined the effect of NgR2 and its co-receptor LINGO-1 using primary cortical 
neurons.  
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Our co-immunoprecipitation data indicated that NgR2 could also interact with 
the co-receptors (both LINGO-1 and p75NTR) originally found to mediate neurite growth 
inhibitory signaling of NgR1 (Fig 4.7). In Neuro2A cell lines stably NgR1 or NgR2 that 
we have generated, we have observed a rather interesting down-regulation of LINGO-1 
expression after differentiation induction with retinoic acid. Using these cell lines, we 
investigated if NgR2 exhibits a neurite growth inhibitory effect by engaging LINGO-1 
as a co-receptor (which was not previously demonstrated). Although Neuro-2A cells 
have detectable endogenous LINGO-1, the NgR1/NgR2 stably expressing cells are not 
significantly affected by MAG-Fc (Fig 4.9). However, cells over-expressing transiently 
transfected LINGO-1 are responsive to MAG and exhibited morphologies consistent 
with inhibition of neurite extension and cell adhesion/migration. Furthermore, we have 
attempted, but failed to obtain any NgR1/NgR2-LINGO-1 double-stable clones in 
Neuro2A. Our results, taken together, provide the first evidence that like NgR1, NgR2 
could also engage LINGO-1 and inhibit neurite growth. In view of the fact that NgR2 
may be more widely expressed in the brain compared to NgR1, our findings may 
provide an explanation for the lack of enhancement of neuronal regeneration in NgR1 
knockout mice (Zheng et al, 2005). 
Binding of MAI to NgR1 have been shown to activate the actin dynamics 
modulating small GTPase Rho (Niederost et al., 2002, Schwab 2004, Mimura et al., 
2006), a signaling path that is well conserved amongst MAIs and axonal guidance 
factors alike (Guan and Yao 2003, Giniger 2002, Dickson 2002, Yiu and He 2006). We 
have therefore also attempted to examine if Rho is activated by Neuro2A cells stably 
expressing NgR2 transfected with LINGO-1. However, no clear elevation of activated 
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RhoA (ie. Rho-GTP) was detected after MAG-Fc stimulation compared with BSA 
control. One likely explanation for our failure in detecting Rho activation is the poor 
transfection efficiency and low endogenous level of LINGO-1. 
5.3 Concluding remarks 
In work reported in this thesis, I have investigated the CNS expression pattern of 
two LRR domain containing proteins that are both brain-enriched, but have apparently 
contrasting functions. AMIGO is a neuronal Ig family cell adhesion molecule that has 
been previously implicated in the enhancement of hippocampal neuron growth. My 
specific novel results pertaining to investigations on AMIGO include the finding that its 
expression is not restricted to neurons, but could also be found in astroglia and 
oligodendroglia. Furthermore, I have shown that AMIGO is primarily localized to 
dendrites, and not axons. Functionally, I have also shown that silencing of AMIGO 
expression impaired dendritic outgrowth in primary cortical neurons. 
NgR2 is a homologue of NgR1, the principal receptor of myelin-associated 
inhibitor of neuronal growth. My specific novel results with regards to work on NgR2 
include the finding that it is more ubiquitously expressed in the adult brain compared to 
NgR1, which suggest that it could be more relevant to inhibition of neuronal 
regeneration in vivo. Furthermore, I have shown that NgR2 binds to LINGO-1 and 
p75NTR, both co-receptor of NgR1, and its engagement of LINGO-1 resulted in a 
responsiveness of Neuro2A cells to neurite extension inhibition by MAG. These 
findings may provide an explanation for the rather puzzling finding that NgR1 knockout 
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did not drastically enhance neuronal regeneration, and may shift our attention to 
developing NgR2 inhibitors for clinical intervention of CNS injury. 
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emerging group of central nervous system-enriched, type I surface proteins with an
ectodomain containing LRR repeats and motifs found in cell adhesion molecules. Members
of this group include the Amphoterin-induced gene and ORF-1 (AMIGO-1), LRR and Ig
domain containing Nogo Receptor interacting protein I (LINGO-1) and the netrin-G1 ligand
NGL-1. The above proteins carry, in addition to the LRR repeats, an immunoglobin (Ig)-like
segment in their ectodomain. Two other related families of molecules, the NLRRs and the
FLRTs, have in addition, a fibronectin type III repeat. The LRR domain distinguishes these
molecules from the more extensively studied Ig-like family of cell adhesion molecules, and
the transmembrane domain differentiate them from the family of secreted extracellular
proteoglycans with LRRs. Functionally, many members of this group of proteins could
modulate neurite outgrowth of neurons, at least in vitro. LINGO-1, initially discovered as a
component of the Nogo-66 receptor complex which inhibits neurite growth, also regulates
oligodendrocyte differentiation and myelination. Current knowledge and recent findings
pertaining to the functions of this interesting group of proteins in the nervous system are
discussed.
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Leucine-rich repeats (LRR) are solenoid-type motifs present in
a number of proteins with diverse functions and cellular
locations (Kobe and Deisenhofer, 1994; Buchanan and Gay,
1996; Kajava, 1998; Kobe and Kajava, 2001). The LRRs are
generally 20–29 amino acids in length which contain a
conserved sequence of LxxLxLxxN/CxL (where x can be any
amino acid and L could also be replaced by V, I or F) (Kobe and
Kajava, 2001). Structurally, each LRR consists of a β-strand
and an α-helix connected by loops, and LRRs in a repeat are
generally arranged in a curved, horseshoe-shaped structure
parallel to a common axis. The LRR repeats are protein–
protein interaction motifs and are found in a large number of
proteins, and these could be divided into subfamilies based
on the consensus sequence of the repeat (Kobe and Kajava,
2001).
Some LRR-containing, plasma membrane localized pro-
teins have more exclusive brain-enriched expression than
others, implying specific functions in the central nervous
system (CNS). The neuronal cell surface Nogo-66 receptor
(NgR) (Fournier et al., 2001) and one of its cognate ligand, the
oligodendrocyte myelin glycoprotein (OMgp) (Vourc'h and
Andres, 2004) form an inhibitory axis of signaling that under-
lies inhibition of axonal growth regeneration after CNS injury
(Filbin, 2003). The NgR is a member of a family of homologous
glycosylphosphatidyl inositol (GPI)-anchored, LRR-containing
proteins with very similar domain structures (Lauren et al.,
2003a; Pignot et al., 2003; Barton et al., 2003), while OMgp is an
NgR ligand with an extracellular LRR domain (the other NgR
ligands being Nogo-66 and myelin-associated glycoprotein
(MAG); Filbin, 2003). The OMgp/Nogo/MAG-NgR axis repre-
sents one known signal pathway whereby the myelin-rich
adult CNS environment inhibits regeneration of injured CNS
neurons (for recent reviews, see Filbin, 2003; McGee and
Strittmatter, 2003; Hunt et al., 2002) (Fig. 1).
Contrasting to neuronal growth inhibition, members of the
Trk receptors are LRR domain-containing receptor tyrosine
kinases which are key neuronal membrane receptors in
transmitting survival and growth signals of the neurotrophin
family of ligands in most neurons (Teng and Hempstead,
2004). The LRR-containing secreted protein Slit (Wong et al.,
2002a), functioning through the roundabout (Robo) membrane
receptors, is a well-known axonal guidance molecule and also
functions in axonal branching and cell migration (Piper and
Little, 2003). Recently, a family of six structurally related mice
LRR-containing, transmembrane proteins have been de-
scribed. These proteins also have homology to Trk in their
intracellular domain and are fittingly named Slitrks (Aruga
and Mikoshiba, 2003). The Slitrks are enriched in differentparts of the brain and appear to have contrasting roles in
modulating neurite outgrowth (Aruga and Mikoshiba, 2003).
Excellent recent reviews of the molecules described above
exist, and the reader is referred to these for an updated review.
Instead, the focus here shall be on a distinct class of CNS-
enriched, type I membrane proteins with leucine-rich repeats
and a domain usually associated with cell adhesion molecule.
These include the AMIGO (Alivin) family, the LINGO family,
NGL-1, the neuronal leucine-rich repeat (NLRR) proteins and
PAL (Fig. 2). All these have a number of LRR repeats flanked by
an N-terminal (LRRNT) and a C-terminal (LRRCT) LRR-like cap.
Furthermore, all these harbor a single C2-type immunoglobin
(Ig)-like domain. The NLRRs and PAL have, in addition, a
fibronectin type III (FN-III)-like repeat. Another family, the
fibronectin-like domain and leucine-rich repeat containing
transmembrane proteins (FLRTs), has a FN-III repeat but no Ig-
like domains. All these molecules have some sort of neurite
growth modulating role, although some are better character-
ized in mechanistic terms than others (Fig. 3). The following
paragraphs constitute a brief survey of these molecules.2. The AMIGO/Alivin family
The genes encoding the AMIGO/Alivin family are initially
identified based on differential display analysis of neurons
(Kuja-Panula et al., 2003). Amphoterin-induced gene and ORF
(AMIGO) was a gene in E18 rat hippocampal neurons induced
by growth on amphoterin (or high-mobility group box 1
protein, HMGB1). Together with two other in silico-identified
homologues, namedAMIGO-2 andAMIGO-3, the threeAMIGOs
form a novel family of type I transmembrane proteins with six
LRRs and a single immunoglobin (Ig)C2-like immunoglobulin
(Ig) located next to the transmembrane segment. Transcript
level analyses indicate that AMIGO is almost exclusively
expressed in the nervous system. The expression of AMIGO-2
andAMIGO-3 ismorewidespread but is also brain-enriched. In
the brain, AMIGO is specifically detected in axonal fibers and
tracts. The ectodomain of AMIGO, when expressed as a heavy
chain (Fc) fusion protein and substratum attached, promoted
neurite extension of cultured hippocampal neurons. Interest-
ingly, when added to the medium, the same AMIGO ectodo-
main-Fc fusion protein inhibited fasciculation of neurites.
Members of the AMIGO family exhibit both homophilic and
heterophilic (to each other) binding activity, which appear to
suggest that they function as novel cell adhesion molecules
that facilitate neuronal growth.
AMIGO-2 was independently identified by a different group
of workers using differential display screening for genes
involved in depolarization and NMDA-dependent survival of
Fig. 1 – Nearest neighbor dendrogram (generated by the MegAlign program of DNASTAR) of the central nervous system-
enriched, type 1 transmembrane LRR and Ig-like domain and/or FN-III domain containing proteins discussed in this review,
together with a number other brain-enriched LRR-containing proteins (such as OMgp, the Nogo-66 receptor paralogues NgR,
NgR2 and NgR3 and Slit). Those proteins not described in the text include nyctalopin (a gene mutated in congenital stationary
night blindness) (Zeitz et al., 2003) and suprachiasmatic nucleus circadian oscillatory protein (SCOP, a brain-enriched protein
which interacts with K-Ras (Shimizu et al., 2003). Opticin is a small LRR proteoglycan expressed exclusively in the eye (Reardon
et al., 2000), while synleurin is a ubiquitously expressed LRR-containing transmembrane protein which when ectopically
expressed in cells intensifies their response to cytokines (Wang et al., 2003). LRRC4 (or NAG14) and LRRC4B (or HSM802162) are
paralogues of NGL-1. Interestingly, LRRC4 has been shown to be exclusively expressed in the brain, is downregulated in brain
tumor tissues and may have a role in suppression of CNS tumors (Zhang et al., 2005). Ribonuclease inhibitor (RI) contains the
prototypic LRR domain and is included for comparison. In the databases, one encounters various nomenclatures and
annotations that may point to the same gene. In this paper, we adopt the most commonly use nomenclature in the primary
literature. Note, however, that according to the nomenclature of the Mouse Genome Infomatics (MGI), NLRR1–NLRR3
corresponded to the genes officially annotated as LRRN1–LRRN3. LRRN4 (not shown) is similar in sequence with leucine-rich
(LR) repeats and calponin homology (CH) domain containing 4 (LRCH4). LRRN5 is GAC-1 as mentioned in the text. LRRN6A is
LINGO-1, LRRN6B is LINGO-3, LRRN6C is LINGO-2 while LRRN6D is LINGO-4. A human NLRR-5 clone reported in Hamano et al.
(2004) is actually LINGO-2.
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named the gene alivin-1 (ali1), after “alive” and “activity-
dependent leucine-rich repeat and Ig superfamily survival-
related protein, and noted the existence of its homologues
alivin-2 and alivin-3 in the database. Expression of alivin-1
transcripts in cultured cerebellar granule neurons is neuronal
activity-dependent-regulated by KCl and/or NMDA concen-
trations in the culture medium, tightly correlated to depola-rization-dependent survival and inhibited when their
spontaneous electrical activity was blocked by tetrodotoxin.
Interestingly, overexpression of alivin-1 in cerebellar granule
neurons inhibited apoptosis induced by a low (5 mM) KCl
medium. Both antialivin-1 antiserum and a bacterially
expressed segment of alivin-1 extracellular domain added to
aprosurvival, high (25mM)KCl culture, attenuated the survival
of the granule neuron. These results suggest that expression of
Fig. 3 – Table summarizing some characteristics and known neurite growth modulating properties of the group of proteins
discussed in this review.
Fig. 2 – Schematic diagram showing the domain organization of representatives of the group of proteins discussed in this
review.
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al of cerebellar granule neurons, and perhaps also hippocam-
pal neurons and the granule cells of the dentate gyrus where it
is expressed.
An interesting recent discovery is in line with alivin-1/
AMIGO-2 role as a cell survival promoting factor as demon-
strated above for cerebellar granule neurons. AMIGO-2 was
identified in a different context—as a gene differentially
expressed in human gastric adenocarcinomas (DEGA), in
approximately 45% of tumor versus normal tissue from gastric
cancer patients (Rabenau et al., 2004). Knockdown of DEGA/
AMIGO-2 by a stable expression of an antisense construct in a
gastric adenocarcinoma cell line led to morphological and
genetic changes that are suggestive of a potential etiologic role
for DEGA/AMIGO-2 in gastric adenocarcinoma, such as pro-
moting the survival of cancer cells.3. LINGO-1
As mentioned in the introductory section, the Nogo/OMgp/
MAG-NgR signaling axis has a major role in the unfortu-
nate inhibition of neuronal regeneration in spinal cord and
brain injury. The NgR, being a GPI-anchored protein,
functions through a membrane spanning coreceptor in
order to transduce growth inhibitory signal generated by
its interaction with myelin-associated inhibitors. The first
such coreceptor identified is the p75NTR (Wang et al., 2002;
Wong et al., 2002b), and engagement of p75NTR and NgR by
the myelin-associate inhibitors results in the activation of
RhoA (Yiu and He, 2003). However, this only happens in
susceptible neurons. In reconstituted non-neuronal sys-
tems, coexpression of NgR and p75NTR did not result in
activation of RhoA, suggesting the existence of additional
NgR coreceptors in susceptible neurons that are missing in
other, non-neuronal systems. LINGO-1, first identified based
on his homology to the guidance molecule Slit (Mi et al.,
2004), is a type I transmembrane protein with 12 LRRs and
a Ig-like domain. Its cytoplasmic tail has a canonical EGF
receptor-like tyrosine phosphorylation site (which appears
to be functionally critical for LINGO-1-associated signaling,
see below). LINGO-1 turns out to interact with NgR and
functions as the additional missing component required for
NgR/p75NTR signaling in non-neuronal cells.
LINGO-1 is specifically brain-enriched. There exist three
other homologues of LINGO-1 in the database (designated
LINGOs 2–4). These are lower in transcript abundance com-
pared to LINGO-1 and are ubiquitously expressed (Mi et al.,
2004). A separate report has earlier namedLINGO-1 as LRRN6A/
LERN1 (leucine-rich repeat neuronal protein 1) and demon-
strated its enriched expression in the limbic system and the
neocortex (Carim-Todd et al., 2003). LINGO-1 expression
appears to be regulated by neuronal activity. Its transcript
levels were strongly upregulated (while NgR mRNA was
downregulated) in the dentate gyrus of rat brain after BDNF
or kainite delivery (Trifunovski et al., 2004).
In non-neuronal COS cells, coexpression of human NgR,
p75NTR and LINGO-1 conferred responsiveness to the myelin-
associated inhibitor and NgR ligand OMgp, as demonstrated
by the latter's ability to activate RhoA. Overexpression ofLINGO-1 in neurons enhanced responsiveness to myelin-
associated inhibitors, while expression of a dominant-
negative LINGO-1 construct (with a truncated cytoplasmic
tail) attenuated myelin inhibition of neurite outgrowth. In
addition, exogenously added LINGO-1-Fc fusion protein also
attenuated outgrowth inhibition, presumably by disrupting
the ternary NgR/p75NTR/LINGO-1 membrane complex.
LINGO-1 also interacts with and mediate the action of TAJ/
TROY (Park et al., 2005; Shao et al., 2005), a member of the
TNF receptor superfamily which is more ubiquitously
expressed in the brain than p75NTR, and which could
functionally replace the latter in the NgR membrane
signaling complex.
A more recent report had expanded the CNS function
associatedwith LINGO-1 (Mi et al., 2005). LINGO-1 is found to be
expressed in oligodendrocytes and has a role in modulating
oligodendrocyte differentiation andmyelination. Accordingly,
dominant-negative LINGO-1, LINGO-1 knockdown by RNA
interference (RNAi) introduced via a lentivirus vector or
LINGO-1-Fc all enhanced differentiation and increased myeli-
nation of primary oligodendrocytes in culture. As in inhibition
of neurite outgrowth, LINGO-1 appears to act through the
activation of RhoA. Overexpression of LINGO-1 activates RhoA
and inhibition of oligodendrocyte differentiation andmyelina-
tion while attenuation of LINGO-1 reduced RhoA activity.
Oligodendrocyte–neuron cocultures treated with LINGO-1-Fc
formed well-developed myelinated axons in vitro, with
distinctly defined nodes and internodes. Analysis of LINGO-1
knockout mice revealed that spinal cords from P1 newborns
have more myelinated axon fibers compared to wild type
littermates, and oligodendroglia cultured from thesemice had
a larger percentage ofmature oligodendrocytes thanwild type.
In all, the above results illustratemultiple functions for LINGO-
1 in the CNS.4. NGL-1
Netrins (or the UNC-6 family proteins) are classical, highly
evolutionarily conserved axonal guidance cues which modu-
late the formation of precise connections between neurons
and their targets during development. Acting both as an
attractant and repellent in different developmental contexts,
netrins guide the growing axons of a broad range of neuronal
cell types and also directly influences neuronal cell migration
(Livesey, 1999). Their actions are mediated by specific receptor
complexes containing either the deleted in colorectal cancer
(DCC) gene product (in the case of growth cone attraction) or
UNC-5-related proteins (in the case of growth cone repulsion).
A novel netrin subfamily containing multiple isoforms of
glycosyl phosphatidyl-inositol (GPI)-linked plasmamembrane
proteins named Netrin G1, has been identified by a signal
sequence trapping screen (Nakashiba et al., 2000; Yin et al.,
2002). Netrin G1 expression is CNS-restricted but the expres-
sion pattern is distinct from other netrins. Instead of the
ventral midline, netrin G1 is enriched in brain regions
including olfactory bulb mitral cells, the thalamus and the
deep cerebellar nuclei. A most important distinction between
netrin G1 and other netrins is that they bind neither DCC nor
UNC-5.
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elaborate Fc fusion protein binding-based interaction screen of
several cell surface proteins (Lin et al., 2003). NGL-1 is a 640
amino acid type I transmembraneprotein,with an ectodomain
containing nine LRRs (which is the netrin G1 interaction
domain) and an Ig-like domain. The intracellular segment of
92 amino acids has no distinct identity with known intracel-
lular signaling motif, although its sequence predicted the
existence of a potential PDZ binding motif (ETQI) at the C-
terminus.
An interesting feature of NGL-1 expression pattern in the
brain underlies its functional interaction with netrin G1. NGL-
1 is most abundant in the striatum and the cerebral cortex.
These regions are the intermediate and final innervation
targets of thalamocortical axons, on which netrin G1 is
particularly abundant. Substrate bound NGL-1 stimulates
process outgrowth of embryonic thalamic neurons in vitro, a
process that can be attenuated by phosphatidylinositol
phospholipase C (PIPLC) treatment (which cleaves GPI-linked
proteins). On the other hand, soluble NGL-1, injected in the
form of Fc-NGL-1 into the neural tube of chick embryos,
impaired the growth of thalamic neurons. These results
suggest that NGL-1, functioning together with netrin G1, is
important for the growth of thalamocortical neurons.
The exact role of NGL-1 in the CNS development (or
postnatal functions) is still unclear, but one recent finding
on NGL-1 is of notable neuropathological significance. This
pertains to confirmation that the C-terminus of NGL-1 does
interact with a PDZ domain containing protein, namely
whirlin (Delprat et al., 2005). Whirlin is a gene expressed in
cohlea haircells sterocilia andmutation of which underlies the
deaf phenotype of the whirler mouse mutant and the human
autosomal recessive deafness locus DFNB31 (Mburu et al.,
2003). The role of NGL-1 in the neurophysiology of audio
perception remains to be fully elucidated, but it is conceivable
that interaction betweenwhirlin and NGL-1might be involved
in the stabilization of interstereociliar links.5. The neuronal leucine-rich repeat (NLRR)
family, the FLRTs and Pal
The NLRR family of proteins is first identified by library
screening using an LRR domain containing expressed se-
quence tag (EST) clone (Taguchi et al., 1996). The first three
members of the mammalian NLRR family are type I trans-
membrane proteins with an ectodomain containing 11–12 LRR
repeats, a Ig-like domain and a FN-III domain. All three
proteins are largely, but not exclusively brain-enriched. NLRR
homologues have been reported in Xenopus (Hayata et al.,
1998) and zebra fish (Bormann et al., 1999), respectively.
The exact cellular and CNS functions of the NLRRs are
unclear. All three NLRRs have different spatial and temporal
expression patterns. Mouse NLRR-1 is expressed in the
myotome of developing somites but not in the presomitic
mesoderm (Haines et al., 2005). NLRR-2 expression appears
to be prominent only in adults while NLRR-3 exhibits
regulated expression in the developing ganglia and motor
neurons (Haines et al., 2005). The human orthologue of
mouse NLRR-2 has been previously identified as GAC-1, agene amplified and overexpressed in malignant gliomas
(Almeida et al., 1998) (also confusingly known as LRRN5).
NLRR-3 expression has been shown to be upregulated during
cortical injury (Ishii et al., 1996). Likewise, the zebra fish
zfNLRR is also prominently expressed during CNS regener-
ation (Bormann et al., 1999). NLRR-3 expression appears to
modulate Ras-MAP kinase (MAPK) pathway signaling and is
induced by epidermal growth factor (EGF). It was suggested
that an endocytosis signal motif at the cytoplasmic tail of
NLRR-3 interacts with the clathrin-associated AP2 adaptor
complex and may facilitate internalization of EGF via
clathrin-coated vesicles, thereby potentiating MAPK signal-
ing in the brain (Fukamachi et al., 2002). A recent report also
identified a novel member of the NLRR family, named NLRR-
4, which is without the Ig-like domain present in all other
members of the family. Interestingly, NLRR-4 knockout mice
have apparent defects in hippocampal-dependent memory
retention (Bando et al., 2005).
FLRTs 1–3 comprise a novel gene family isolated in a screen
for extracellular matrix proteins expressed in muscle (Lacy et
al., 1999). These have 10 LRRs and an FN-III domain. All three
members of the family are expressed in the brain, with FLRT-1
being the most brain-enriched.
FLRT-3, which is widely expressed, has demonstrated roles
in neuronal function. One report indicated that FLRT-3 mRNA
is abundant in specific regions of the adult rat brain, is
upregulated in the distal segment of transected sciatic nerve
and promotes neurite outgrowth of cultured cerebellar
granule neurons (Tsuji et al., 2004). Another report showed
that FLRT-3 regulate neurite outgrowth of sensory neurons of
the peripheral nervous system (Robinson et al., 2004) and is
upregulated during peripheral nerve injury (but not in CNS
nerve injury). Studies on the Xenopus homologue FLRT-3
(XFLRT-3) indicated that it is a modulator of fibroblast growth
factor (FGF) signaling, resulting in the activation of the ERK
pathway. XFLRT3 interacts with FGF receptors (FGFRs) both in
vitro and in vivo (Bottcher et al., 2004).
The photoreceptor-associated LRR superfamily (PAL) gene
is a retina-specific gene encoding a putative type I transmem-
brane protein with five LRRs, a single C2-type Ig-like domain
and a single fibronectin type III domain (Gomi et al., 2000).
Identified in a screen for retina-specific genes by differential
display, it has an interesting postnatal onset expression
profile. The expression patterns of Pal (detectable only at
around P7 and increases thereafter) appeared to be correlated
with the development of the photoreceptor outer segments. In
the adult rat retina, it is indeed specifically localized at these
segments. The protein is distributed diffusely on the disk
membrane in the lamellar regions as shown by immunogold
electron microscopy. Not much is known yet about the actual
physiological function of PAL although it is likely an adhesion
molecule functioning specifically in retinal morphogenesis.6. Other nervous system-associated
LRR-containing transmembrane proteins
The family of LRR-containing molecules discussed above is
distinct from the small leucine-rich proteoglycans (SLRPs)
(Iozzo, 1997, 1999, Hocking et al., 1998; Ameye and Young,
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transmembrane Ig-superfamily of cell adhesion molecules,
or Ig-CAMs (Walsh and Doherty, 1997) that are brain-
enriched but without LRR repeats in their ectodomains.
Another possible member of the group is the brain-
enriched LRIG-1 (or LIG-1) (Suzuki et al., 1996) and its
ubiquitously expressed paralogues (Guo et al., 2004). LRIG-1
(and its likely Drosophila homologue Kekkon; Musacchio
and Perrimon, 1996) binds to the epidermal growth factor
(EGF) receptor and inhibits its signaling (Gur et al., 2004;
Laederich et al., 2004). However, LRIG-1's deletion resulted
in no apparent neuronal defects. Instead, LRIG-1 deficient
mice develop a skin condition after birth that is pheno-
typically reminiscent of the skin disease psoriasis (Suzuki
et al., 2002).
The proteins discussed above also did not include those
transmembrane proteins found in the brain that has LRR
repeats, but without any Ig-like or FN-III domains. Prominent
members of the latter group include the brain-enriched LGI-1
(a gene implicated in epilepsy and tumor suppression (Cher-
nova et al., 1998; Gu et al., 2005) and its more ubiquitously
expressed homologues (Gu et al., 2002)). Lib is identified as a
gene upregulated by beta-amyloid treatment of rat astrocytes
(Satoh et al., 2002), but is actually most enriched in placenta.
Another family of brain-enriched LRR repeat containing
transmembrane proteins is the LRRTMs (Lauren et al., 2003b).
LRRTMs (except for LRRTM4) are peculiar in the genomic sense
that they are located in the introns of different alpha-catenin
genes, and that these two gene families may have coevolved.7. An emerging group of brain-enriched, LRR
repeat and cell adhesion motif containing
transmembrane proteins—interactions and
signaling
Collectively, the above described appear to be a group of
proteins with similar functional domains but are heteroge-
neous in their physiological roles in the CNS. By virtue of the
presence of extracellular Ig-like and FN-III domains, the group
of proteins discussed above might function in modulating
neuronal cell adhesion. Such cell–cell or cell substratum
adhesions are important for both dynamic developmental
processes such as axonal pathfinding, as well as architectural
purposes such as organizational stability of the synapses or
axoglial junctions. The Ig-like domain in particular is the
signature motif for the immunoglobulin superfamily of
adhesion molecules (Kamiguchi and Lemmon, 2000). The
presence of Ig-like domains, in tandemwith the LRR domains,
potentially broadens the repertoire or enhances the potential
for a wide spectrum of multiple protein–protein interactions
by members of this family.
However, only members of the AMIGO/Alivin have been
shown to interact homotypically and heterotypically with
each other in trans (i.e. between two cells). The interaction
between NGL-1 and netrin G should also be in trans, but this is
more likely to serve a guidance rather then an architectural,
cell-adhesion role. LINGO-1's interaction with NgR and p75NTR
or TAJ/TROY is likely in cis (i.e. on the same plasma
membrane), as would FLRT3's interaction with FGFR. ForLINGO-1, the formation of the ternary LINGO-1/NgR/p75NTR
complex on neuronal growth cones is essential for inhibition
of neurite growth, but whether the same complex is necessary
for modulation of oligodendrocyte differentiation and myeli-
nation has not yet been demonstrated. It is yet unclear if any
of these proteins have high affinities for extracellular matrix
components, and if any of them have a role in cell–matrix
interaction and inside-out or outside in signaling. NLRRs and
FLRTs with FN-III domains could potentially interact with
integrins, but this has not been clearly demonstrated. It is
interesting to note that within the same molecule, the LRR
motifs could potentially modulate the functional interaction
of the Ig-like domains with other proteins and vice versa. We
have, for example, observed that these motifs, when over-
expressed individually, have noticeable differences in their
effects on cell morphology (Aulia and Tang, unpublished
results). Future explorations would undoubtedly reveal more
on the interactive partnerships of these proteins with others.
The particularly interesting property of these proteins,
which functionally cluster them into a noticeable group, is
their potential role in modulating neurite growth. In this
respect, there is much room for further investigations, as only
the downstream signaling of LINGO-1 and FLRT3 is known to
any extent. Clearly, all these proteins could either signal
intracellularly through their cytoplasmic domains or by
engagement of other transmembrane proteins in a signaling
complex. The cytoplasmic domains of the AMIGO/alivin
paralogues and NGL-1 paralogues are rather divergent from
one another andmotif scans reveal no known signaling motif.
The LINGO paralogues have a putative tyrosine kinase
phosphorylation site that is conserved in LINGOs1–3, but not
LINGO-4. It is yet unclear if this tyrosine residue is indeed
phosphorylated in a regulated manner in vivo. NLRR-1 and
NLRR-3 have a conserved endocytosismotif at the cytoplasmic
tail that is not present in NLRR-2. The latter has instead a
putative WW domain, a protein interaction motif binding to
polypeptide stretches that are proline-rich (Ilsley et al., 2002).
The FLRTs have a conserved tyrosine kinase phosphorylation
site at their cytoplasmic domain which could be a potential
substrate for FGFR.
Of the protein families emphasized above, only LINGO-1
and NLRR-4 have been analyzed at the level of targeted gene
disruption. It turns out that although LINGO-1 is not essential
for embryonic development, it undoubtedly has some roles to
play in postnatal development of the nervous system (as
gleaned from the fact that LINGO-1 deficient oligodendrocytes
mature and differentiate faster) (Mi et al., 2005). NLRR-4 has a
subtle, but phenotypic memory impairment that is highly
interesting and which warrants further investigations. A
combination of gene knockout and nervous system-specific
transgenic overexpression of these molecules, alone and in
combinations, would yield much more information on their
interactions and functions.8. Epilogue
Elaboration of the vertebrate CNS had likely benefited from the
expansion and evolution of these complex arrays of signaling
molecules, forming an intricate web of growth and
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the functions and mechanism of function of this emerging
group of transmembrane proteins with LRR repeats and cell
adhesion molecule motifs would clearly provide useful
insights to CNS physiology and pathology. If the recent
elucidation of involvement of leucine-rich repeat kinase 2
(LRRK2)/dardarin in Parkinson disease (Singleton, 2005) is
anything to go by, we could expect to hear much more about
LRR repeat-containing proteins in the brain in the near future.Acknowledgments
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Introduction
The myelin-associated glycoprotein (MAG)
is a type 1 transmembrane protein found in the
peri-axonal membrane of both the central ner-
vous system (CNS) and peripheral nervous
system (PNS) myelin sheaths. Alternatively,
splicing results in two isoforms: small (S-; 582
residues) and large (L-; 626 residues) MAG (1).
In rodents, L-MAG levels peak during CNS
development and decline in adulthood, but S-
MAG is the predominant form in both adult
PNS and CNS (2). Conversely to rodents, the
human L-MAG splice variant predominates in
adult human brain, whereas human S-MAG is
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Abstract
The myelin-associated glycoprotein (MAG) is a type I membrane-spanning protein expressed
exclusively in oligodendrocytes and Schwann cells. It has two generally known pathophysiologi-
cal roles in the central nervous system (CNS): maintenance of myelin integrity and inhibition of
CNS axonal regeneration. The subtle CNS phenotype resulting from genetic ablation of MAG
expression has made mechanistic analysis of its functional role in these difficult. However, the
past few years have brought some major revelations, particularly in terms of mechanisms of MAG
signaling through the Nogo-66 receptor (NgR) complex. Although apparently converging
through NgR, a readily noticeable fact is that the neuronal growth inhibitory effect of MAG differs
from that of Nogo-66. This may result from the influence of coreceptors in the form of ganglio-
sides or from MAG-specific neuronal receptors such as NgR2. MAG has several other neuronal
binding partners, and some of these may modulate its interaction with the NgR complex or
downstream signaling. This article discusses new findings in MAG forward and reverse signaling
and its role in CNS pathophysiology.
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most abundant in the PNS (3). Both forms dif-
fer only in the cytoplasmic C-terminus but
have the same N-terminal extracellular
domain, which contains five immunoglobulin-
like motifs. MAG is a member of the sialic
acid-dependent immunoglobulin-like family
member lectins (siglec) family (4). Because
MAG is designated siglec-4a, much, but not
all, of its interaction with neurons occurs in a
sialic-acid-dependent manner (5).
Despite being initially described as a protein
that confers neural adhesion and neurite out-
growth function (6), it soon became apparent
that MAG is a myelin-associated inhibitor of
neurite outgrowth and axonal regeneration
(5,7–9), at least in vitro and when examined
using adult neurons. Recombinant MAG coated
onto beads induces hippocampal neuron
growth cone collapse (9). Proteolytically gener-
ated, soluble MAG consisting of the extracellu-
lar domain is also a potent inhibitor of neurite
outgrowth (10,11). However, analysis using
MAG knockout mice (12) has not provided
strong support to the notion of MAG as a major
CNS neurite growth inhibitor. There was no
apparently significant difference in cell spread-
ing, neurite elongation, or growth cone collapse
of several cell types when myelin preparations
from either MAG-deficient or wild-type mice
were used as a substrate. Furthermore, the
extent of axonal regrowth in optic nerve and
corticospinal tract lesions in vivo was equally
poor in MAG-deficient and wild-type mice.
Because axonal regrowth in MAG-deficient
mice could be similarly enhanced in wild-type
mice by the Nogo-targeting antibody IN-1, it
appears that MAG does not carry the majority
of the neuronal growth inhibitory activity of
myelin.
Earlier investigations using oligodendrocyte
neuron cocultures and the analysis of MAG-
deficient mice also suggested a role for MAG
in the initiation of CNS myelination as well as
the long-term preservation of myelin sheaths
(extensively reviewed in ref. 13). Again, how-
ever, the subtlety of the phenotypes observed
made it difficult to view MAG as a major func-
tional component of myelin. It is obvious that
other oligodendroglia components could func-
tionally cover for the complete absence of
MAG during development. MAG maybe
involved in reverse signaling processes in
oligodendrocytes, because crosslinking of
MAG with antibodies activates Fyn tyrosine
kinase (14,15). The latter phosphorylates the
cytoplasmic domain of L-MAG, which is the
longer splice isoform specifically involved in
CNS myelination (16), principally at tyr 620
(17). Mild hypomyelination was observed in
optic nerves of MAG-deficient mice. This is
worse in Fyn-deficient mutants, and the sever-
ity of the defects were additive in MAG/Fyn
double mutants (18), suggesting that although
both MAG and Fyn are important for the initi-
ation of myelination, they may nonetheless act
independently.
The past 3 yr had provided substantial
breakthroughs in our understanding of the for-
ward signaling of MAG. In 2002, MAG was
shown to interact with the leucine-rich repeat
(LRR)-containing, GPI-linked Nogo-66 recep-
tor (NgR) (19), which transduces its growth
inhibitory effect on neurons (20,21). The latter
was initially cloned as a neuronal receptor
mediating the neurite outgrowth inhibition by
the extracellular 66-amino acid loop (termed
Nogo-66) common to all major splice isoforms
of Nogo (22), the target of the neurite growth-
enhancing IN-1 antibody (23). Another myelin-
associated protein, oligodendrocyte-myelin
glycoprotein (OMgp), also inhibits neurite
growth through the NgR. The NgR transduces
a growth inhibition signal by engaging the
transmembrane p75NTR (24,25) or TAJ/TROY
(26,27) in conjunction with another LRR-con-
taining transmembrane protein known as
LINGO-1 (28). Signaling through p75NTR ulti-
mately leads to the activation of Rho and its
effectors, resulting in changes of the actin
cytoskeleton that underlie growth cone col-
lapse or repulsion (29).
In the midst of these new developments, it
should be emphasized that the effect of MAG
on neurite growth is qualitatively different
from that of Nogo-66. This article reviews new
findings on MAG’s forward inhibitory signal-
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ing to neurons, highlighting the differences
with that of Nogo-66 and citing references to
MAG’s neuronal binding partners. It then
briefly surveys some new implications of
MAG in CNS pathology.
MAG’s Neuronal Interacting
Partners I: Sialoglycolipids
In the CNS, MAG is localized to myelin mem-
branes juxtaposed to axons (30), and purified
MAG protein incorporated into liposomes
binds neuronal processes (6). Although much of
the recent excitement has focused on MAG’s
interaction and action through the NgR, the lat-
ter is not the only neuronal molecule interacting
with MAG. A prominent feature of MAG–neu-
ron interaction is dependency on sialic acid, a
feature that is not apparent in earlier reports of
MAG–NgR interaction (20,21). MAG binds best
to 2,3-linked sialic acid on a Gal(β1→3)GalNac
core structure (31,32). Interestingly, MAG’s
sialic acid binding site is actually distinct from
its neurite inhibitory activity. This was elegantly
illustrated as a truncated form of soluble recom-
binant MAG (MAG-Fc; containing Ig domains
1, 2, and 3 but missing domains 4 and 5, fused to
the immunoglobulin heavy-chain), which was
bound to neurons in a sialic-acid-dependent
manner but did not inhibit neurite outgrowth
like full-length MAG. Mutation of arginine 118
(R118) in MAG to either alanine or aspartate
abolished its sialic-acid-dependent binding.
However, R118-mutated MAG retained a weak-
ened capacity of inhibiting neurite outgrowth
and remained a potent inhibitor when
expressed at cell surfaces rather than being
added as a soluble protein (33).
The sialic acid moiety alluded to earlier is
often found on a class of glycosphingolipids
known as gangliosides, and MAG has been
shown to bind a limited set of structurally
related gangliosides known to be expressed in
myelinated neurons. These include the major
brain ganglioside GD1a and GT1b, as well as
a minor ganglioside GQ1bα, expressed on
cholinergic neurons (34–36). Gangliosides
mediate MAG’s inhibition of neurite out-
growth from primary rat cerebellar granule
neurons, because the latter is clearly attenu-
ated by neuraminidase treatment of the neu-
rons, blocking of neuronal ganglioside
biosynthesis, or antiganglioside monoclonal
antibodies. Furthermore, multivalent cluster-
ing of GD1a or GT1b using precomplexed
antiganglioside antibodies mimicked MAG’s
inhibitory effect (35). An earlier study showed
that antibody-crosslinking of cell surface
GT1b, but not GD1a, mimicked the effect of
MAG. Notably, the Rho kinase (ROCK)
inhibitor Y27632 blocked inhibition of neurite
outgrowth by both MAG and anti-GT1b anti-
body. Activation of Rho-ROCK is a universal
convergent point downstream of neurite out-
growth inhibitors, including all the major
neuronal guidance ligand-receptor systems
(37). Therefore, the gangliosides appeared to
be an authentic neuronal MAG receptor medi-
ating its neurite growth inhibitory function.
Because gangliosides are not membrane-
spanning structures with a sizable cytoplasmic
domain, they are incapable of relaying a signal
to the cytoplasm. The initial picture of MAG
signaling through gangliosides is that MAG
binding causes ganglioside clustering in lipid
rafts, which somehow results in the activation
of signaling proteins found in such membrane
microdomains. In other words, MAG-induced
ganglioside clustering presumably leads to the
activation of a coreceptor(s). It is apparent that
p75NTR is a promising candidate for such a
coreceptor (38). Adult dorsal root ganglion
neurons or postnatal cerebellar neurons from
mice that are null for functional p75NTR are
insensitive to MAG inhibition and Rho activa-
tion. MAG does not appear to interact directly
with p75NTR but could associate with it
through GT1b (which specifically associates
with p75NTR). Additionally, the newly discov-
ered Nogo–NgR system also searches for a
transmembrane signaling coreceptor. Based on
these leads, research has demonstrated that
MAG, similarly to Nogo-66 (and OMgp), can
bind NgR and engages p75NTR in neurite
growth inhibitory signaling (24,25).
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If we have a direct link between MAG and
p75NTR in the form of NgR, are the gangliosides
still necessary? The answer appears to be affir-
mative, and therein is one major difference
between MAG and the other NgR ligands.
Analysis of mice that were deficient in β1, 4-N-
acetylgalactosaminyltransferase (ref. 39; there-
fore lacking all complex gangliosides in the
brain, including GD1a and GT1b) indicated that
its neurons were no longer susceptible to the
growth inhibitory effect of MAG-Fc but
remained sensitive to Nogo-66 peptide (40). On
the other hand, mice deficient in GD3 synthase
(lacking the b-series gangliosides—that is, those
with GD1a but not GT1b; ref. 41) were still sus-
ceptible to both MAG-Fc and Nogo-66. Ganglio-
sides are apparently also necessary for MAG’s
activation of Rho. Interestingly, both MAG-Fc
and Nogo-66 peptide induce clustering of
p75NTR into lipid rafts. The latter appears to be
required for the growth cone collapsing activity
of myelin-associated inhibitors, because this
activity is abolished by cholesterol extraction
with methyl-β—cyclodextrin (40). It is clear
from the aforementioned findings that ganglio-
sides plays a role in modulating spatial, and
perhaps temporal, response of axons to MAG in
a way Nogo-66 is not subjected to.
How exactly does engagement of NgR and
p75NTR by MAG activate Rho? In the cell, Rho
is kept inactive in the cytosolic pool by its
binding to the Rho GDP dissociation inhibitor
(RhoGDI) (42). p75NTR–RhoGDI interaction is
apparently strengthened by the binding of
MAG or Nogo to the receptor complex, and
therefore, p75NTR could activate Rho by some-
how displacing it from RhoGDI. A new insight
to this theory has been obtained. p75NTR was
known to undergo ectodomain shedding and
regulated intramembrane proteolysis, an α-
secretase-mediated process that generates an
extracellular domain and a C-terminal motif.
The latter is further cleaved by the γ-secretase
complex to generate an intracellular domain
(43,44). Filbin et al. (45) have shown this PKC-
dependent cleavage of p75NTR by to be
induced by MAG binding to cerebellar neu-
rons, and it is necessary for Rho activation. As
mentioned earlier, p75NTR activates Rho, pre-
sumably by acting as a displacement factor
that realeases Rho from Rho-GDI (46). This
finding has provided some possible resolution
to the paradoxical observation that endoge-
nous p75NTR is in complex with Rho–RhoGDI
and that MAG/Nogo-66 binding appears to
strengthen existing p75NTR–Rho–RhoGDI com-
plexes rather than weaken it. Therefore, upon
cleavage the intracellular domain fragment of
p75NTR, unlike full-length p75NTR, could per-
turb RhoGDI’s ability to inhibit GTP–GDP




Gangliosides are also not the only neuronal
molecules that interact with MAG, because
MAG-Fc binding to neurons is sensitive to
trypsin (47), and a pull-down screen revealed
several high-molecular-weight proteins inter-
acting specifically with trypsin (48). Two NgR
homologs (designated NgR2 and NgR3) were
recently identified in the mammalian genome
(49–51), but preliminary analyses provided the
impression that these did not bind the known
NgR ligands.
However, a more recent in-depth analysis
revealed that MAG exhibits a sialic-acid-
dependent affinity for NgR2 that was several-
fold higher than NgR (52). Interestingly, the
study also revealed that MAG’s interaction
with NgR is sialic-acid-dependent, whereas
Nogo-66’s interaction with NgR was not.
Additionally, Nogo-66 does not interact with
NgR2. Therefore, in addition to that observed
for the sialoglycolipids, MAG and Nogo dif-
fer in terms of sialoglycoprotein binding. Per-
taining to MAG, NgR2 appears to have a role
analogous to NgR because its ectopic overex-
pression in neurons confers susceptibility to
inhibition by MAG. However, it has not been
determined whether this inhibition also
occurs via the engagement of p75NTR/TAJ
(and/or LINGO-1) as in the case of NgR.
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MAG Signaling and Axon–Glia
Pathology
MAG–ganglioside interaction goes beyond
the signaling of neurite growth inhibition. In
fact, it has been proposed that at least some of
MAG’s interaction with its neuronal ganglio-
side ligands is a lipid raft-to-lipid raft affair
occurring on opposing oligodendroglia and
axonal membranes (53). This implies a struc-
tural organization for bidirectional signaling
that may be important for the stabilization of
the axon–glia interaction. Mice lacking complex
gangliosides as a result of a deletion of
GM2/GD2 synthase developed Wallerian
degeneration, myelination defects, and, interest-
ingly, a reduction in CNS MAG levels (54).
Researchers recently reported that when back-
crossed to a more than 99% C57BL/6 strain
purity, MAG-deficient mice exhibited marked
CNS (as well as PNS) axonal degeneration (55)
that was qualitatively similar to mice deficient
in β1, 4-N-acetylgalactosaminyltransferase (39).
As mentioned earlier, MAG is apparently
connected to oligodendrocyte differentiation
and myelination via its interaction with Fyn
kinase. Therefore, a particular recent finding is
noteworthy. Mi et al. (56) found that LINGO-1 is
also expressed in oligodendrocytes and further
showed that it appears to regulate myelination.
Accordingly, attenuation of LINGO-1 expres-
sion or activity in primary oligodendrocytes
increases myelination competence, whereas the
overexpression of LINGO-1 inhibits olig-
odendrocyte differentiation and myelination.
LINGO-1 affects the aforementioned processes
via modulation of the expression and phospho-
rylation of Fyn, as well as the activation of Rho.
The exact mechanism by which this is achieved
is unknown, as is how MAG could be involved
in this connection. On one hand, LINGO-1
action in oligodendrocytes may occur via path-
ways and signaling components independent of
MAG until their convergence at Fyn and Rho.
However, although MAG’s interaction with the
neuronal NgR complex containing LINGO-1
occurs in trans, it is not entirely inconceivable
that MAG might interact in cis with a similar
complex in oligodendrocytes and might modu-
late its activity somewhat. These possibilities
remain to be explored.
MAG and Other CCNS
Neuropathology
An interesting recent finding implicated
MAG’s involvement, for the first time, in a
human hereditary disorder: familial late-onset
orthochromatic leukodystrophy (57). This
genetic neurological disease has no clear signs
of neuropathy. Analysis of two members of an
Italian family with the disease indicated their
brain myelin contained a truncated from of L-
MAG that is about 5 kDa shorter than wild-
type. The defect is not the result of a mutation
in either the coding or untranslated region of
the MAG gene, and the alteration in MAG is
likely to be secondary to a yet unknown pri-
mary defect that resulted in their production
with age. It is unclear how this truncated form
of L-MAG affects the CNS white matter. It
should be noted that unlike rodents, L-MAG is
the predominating form in the adult human
CNS. Therefore, any alteration to the protein is
likely to result in either a loss- or gain-of-func-
tion defect that could lead to oligodendroglial
or neuronal pathology.
Another aspect of MAG that has been
recently explored involves its use as a therapeu-
tic target in CNS injuries. Preclinical interven-
tion models targeting the NgR with in situ
delivery of dominant-negative NgR proteins
showed significant benefits in optic nerve injury
and stroke (58,59). However, a MAG-specific
agent for CNS injury has not been developed
and explored until recently. There are indica-
tions that a MAG-specific agent may be benefi-
cial in brain injuries such as stroke. In the rat, it
has been shown that L-MAG is re-expressed in
oligodendrocyte cytoplasms in the white matter
around experimental cerebral infarcts produced
by middle cerebral artery occlusion (MCAO)
(60). MAG expression is elevated in cortical
lesions, and neuraminidase treatment of axo-
tomized entorhino-hippocampal cultures
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potentiates axonal regeneration (61). Irving and
colleagues (62) found that an anti-MAG mono-
clonal antibody that could neutralize the neu-
ronal inhibitory effect of MAG could also
protect oligodendrocytes from glutamate-medi-
ated oxidative stress-induced cell death. Impor-
tantly, this antibody showed significant
beneficial effects in a rat model of MCAO. Cen-
tral and systemic administration of the antibody
1 h after stroke induction significantly reduced
infarct volume at 7 d. Neuroprotection was also
associated with significant improvement in
motor function. This finding indicates the
potential for the use of anti-MAG antibodies as
therapeutic agents for the treatment of stroke.
An emerging aspect of myelin-associated pro-
teins in CNS pathology has occurred in the area
of schizophrenia and bipolar disorder, which
have been associated with oligodendrocyte dys-
function (63,64). MAG has been shown to be
downregulated in schizophrenic brains. Genetic
studies linking polymorphisms at the MAG
locus to schizophrenia have also been reported
recently for Chinese family cohorts (65,66). It
remains to be seen whether these linkages are
borne by more extensive studies, or whether the
association between MAG and schizophrenia
will be as controversial as that of Nogo.
Conclusion
Although a major portion of MAG’s func-
tional effect on neurons in CNS pathophysiol-
ogy is likely to be mediated by NgR, MAG’s
actions differ from that of Nogo-66, as shown
by the availability of ganglioside coreceptors
(see Fig. 1 for a detailed review of some of the
signaling pathways and components associ-
ated with MAG). Neuronal receptors that are
6 Chen et al.
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Fig. 1. A schematic diagram of MAG-associated forward and reverse signaling pathways and components in
the axon–glial system. Engagement of neuronal NgR–p75NTR and LINGO-1 by oligodendroglial MAG mediates
neurite growth inhibition, as measured by growth inhibition assays, resulting in the activation of RhoA and sup-
pression of Rac 1 (not shown here) (29). The receptor complex presumably activates the trimeric G protein Gi
and the downstream phospholipase C–protein kinase C (PKC)/Inositol 1,4,5-triphosphate (IP3) pathways (as
depicted in ref. 67). PKC is activated by both phospholipase C-generated diacylglycerol and the elevation of
growth cone cytoplasmic Ca2+ (a result of IP3-induced Ca2+ release from internal stores). PKC appears to be
important for Rho activation, because PKC inhibitors attenuate MAG’s ability to inhibit neurite growth (68) and
may, in some cases, enhance neurite growth (67). It is unclear exactly how PKC activity might affect Rho activa-
tion (dotted lines), but intramembrane proteolysis of p75NTR by γ-secretase is apparently PKC-dependent (45).
Upon cleavage, the intracellular domain of p75NTR displaces Rho-GDI from Rho, leading to its activation by
guanine nucleotide exchange factors (not shown here).
In growth cone turning assays, p75NTR and NgR are also responsible for the intracellular activation of Ca2+
that resulted in growth cone turning (25). However, the effect of MAG-induced Ca2+ on growth cone behavior is
complex. It may mediate growth cone repulsion or attraction, depending on the exact concentration of Ca2+
elicited (69). This effect is modulated by intracellular cyclic adenosine monophosphate (cAMP) (69,70), which
is elevated by neurotrophin (N) signaling through Trk family receptors. The cAMP elevation has been demon-
strated to overcome MAG’s inhibition of neurite outgrowth (71–73). The modulatory effect of cAMP and protein
kinase A in modulating neurite outgrowth has been extensively reviewed. It is not described here, and the reader
is referred to the excellent and in-depth discussion by Filbin (74) for more details. Note that neurite growth inhi-
bition and growth cone repulsion and attraction are experimental phenomena. Different experimental para-
digms have different emphasis regarding parameters measured. On the whole, it appears that the same set of
pathways and components are engaged, but there may be subtle differences.
Fyn tyrosine kinase is a key modulator of oligodendrocyte differentiation and interacts with MAG. Crosslink-
ing of oligodendroglial MAG by antibodies could result in Fyn phosphorylation. Differentiation of oligodendro-
cytes could be triggered by engagement of the extracellular matrix via integrins, whose signaling via Fyn to Rho
family GTPases regulates morphological differentiation (75). LINGO-1 on oligodendrocytes modulates its differ-
entiation by activating Rho. It is unclear whether MAG has a direct role in this effect of LINGO-1.
MAG-specific, such as NgR2, also confer a
unique neuronal response to MAG. MAG
clearly has other neuronal binding partners
that have yet to be molecularly identified.
Some of these may modulate its interaction
with the NgR complex or downstream signal-
ing, whereas others may have completely
unrelated effects. MAG’s reverse signaling in
MAG-Mediated Signaling in the CNS 7
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oligodendrocytes has remained largely unex-
plored. The availability of promising new
molecular handles may soon change this.
Contra-indicative to the subtlety of its knock-
out phenotype, further investigations in
MAG–neuron interaction and MAG reverse
signaling and continuous exploration of its
value as a therapeutic target in CNS patho-
physiology now appear to be worthwhile
ventures.
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